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ABSTRACT 
 
COPD is a poorly reversible airflow obstruction commonly induced by cigarette 
smoke.  Pathology is linked to a series of inflammatory and fibrotic events in the 
small airways and lung parenchyma; including fibrosis, emphysema and mucus 
plugging.  This work focuses on the inflammatory and fibrotic aspects of COPD 
pathology.  Processes of fibrotic Epithelial to Mesenchymal Transition (EMT) have 
been identified in heart and kidney disorders and we wished to evaluate if this is a 
contributing factor in COPD.   Second, patient treatment options are limited. Steroid 
resistance is the major barrier for effective treatment and this study seeks to 
evaluate steroid receptor expression patterns in COPD patient and control subjects 
to better understand mechanisms of resistance. The aim of this study is to evaluate 
EMT (S100A4) and glucocorticoid receptor (TTC5 & S211) component expression in 
lung tissue of COPD patients and control subjects using immunohistochemical 
staining. The result obtained describes that S100A4 (EMT marker) was more highly 
expressed in active smokers (non-smoker and ex-smoker, versus current, 
p<0.0001).  TTC5 expression was higher in both ex-smokers and current smokers 
compared to NS (p=0.0022).  S211 expression levels were similarly raised in both ex 
and current smokers compared to NS (p=0.0078). The conclusion is that raised 
S100A4 expression in active smokers indicates EMT and may play a role in fibrosis 
in COPD via a partially reversible process. Raised TTC5 and S211 in ex and current 
smokers indicate irreversible glucocorticoid receptor changes and may implicate a 
mechanism of steroid resistance in COPD patients, thus prompting further research 
in this area. 
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 1. INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease represents a major health problem world-
wide. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines 
Chronic Obstructive Pulmonary Disease as preventable and treatable disease 
characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and 
lungs to noxious particles or gases. Chronic Obstructive Pulmonary Disease is a 
leading cause of morbidity and mortality worldwide with an overall prevalence (9-
10%) in adults aged >40 years (Halbert et al, 2006). 
1.1 EPIDEMEOLOGY OF COPD 
In United Kingdom, 1.2 million people have been diagnosed with chronic obstructive 
pulmonary disease, making it the second most common lung disease in country after 
asthma. One patient dies every 20 minutes with COPD in England killing over 23,000 
individuals each year. It is the 2nd most common cause of emergency admissions to 
hospital and one of the most costly inpatient conditions to be treated by the NHS 
(>£800 million each year).  An important feature in the epidemiology of COPD is the 
high risk of under diagnosis (Miravitlles et al, 2009 & Hvidsten et al, 2010), therefore 
the above figure are likely to be an under-estimate and the mortality in the population 
is likely to be much higher. COPD is presently fourth leading cause of death 
worldwide but World Health Organization (WHO) estimates that by 2020, COPD will 
be the 3rd leading cause of mortality and the fifth cause of morbidity in the world. 
The primary cause of COPD is smoking, with 30-40% of smokers estimated to 
develop the disease (Lokke et al, 2006). Chronic Obstructive Pulmonary Disease 
(COPD) is an umbrella term and includes Chronic Bronchitis, Emphysema & Chronic 
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unremitting asthma which can all co-exist in some people with the disease. 
1.1.1 EARLY HISTORICAL BACKGROUND 
 
In 1679, Bonet described emphysema as “Voluminous lungs” and after century later 
in 1769 Morgagni described it as ‘turgid’ from air (Bonet, 1679; Morgagni, 1769, cited 
in Petty, 2006). The clinical understanding of the chronic bronchitis component of 
COPD was traced by Badham in 1814; he used the word catarrh to refer as ‘chronic 
cough’ and Mucus hypersecretion as cardinal symptoms (Badham, 1814, Cited in 
Petty, 2006).  
The description of emphysema of the lungs was found in ‘Treatise of diseases of the 
chest’. Laënnec was the inventor of stethoscope and carried out study by careful 
dissections of patients lungs during his life. He recognized that emphysema lungs 
were hyper inflated and did not empty well. This combination was described as 
emphysema and chronic bronchitis (Laënnec, 1821, Cited in Petty, 2006).   
The spirometer is a key to diagnosis and management of COPD. Spirometer was 
invented in 1846 by John Hutchinson by which only vital capacity was measured 
(Hutchinson, 1846). It took another 100 years for Tiffeneau to add the concept of 
timed vital capacity as a measure of airflow for spirometry to become a complete 
diagnostic instrument (Tiffeneau & Pinelli, 1947).  
The great teachers of emphysema, Ronald Christie, suggested that “the diagnosis 
should be considered certain when dyspnea or exertion of insidious onset, not due to 
bronchospasms or left ventricular failure, appears in a patient who has some 
physical sign of emphysema together with chronic bronchitis and asthma” (Christie 
1944). It is clear from this statement that Christie recognized that individual 
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components of COPD and relied on the history and physical examination for his 
diagnosis.   
1.1.2 TWO LANDMARKS MEETINGS 
The CIBA guest symposium in 1959 (Ciba guest symposium 1959, Donald 1971) 
and the American Thoracic Society Committee on Diagnostic standards in 1962 
defined the components of COPD, which are the foundation for our definitions today 
(Committee on Diagnostic standards for Non-tuberculosis respiratory diseases, 
1962). The American Thoracic Society (ATS) defined chronic bronchitis in clinical 
terms including chronic cough lasting at least three months for at least two years. By 
contrast, the ATS defined emphysema in anatomic terms of enlarged alveolar 
spaces and loss of alveolar walls. Asthma was described as a state of airway hyper 
responsiveness to a variety of stimuli. Asthmatic bronchitis was considered an 
overlapping condition (Committee on diagnostic standards for Non-tuberculosis 
Respiratory Diseases, 1962).  
William Briscoe is believed to be the first person to use the term COPD in discussion 
at the 9th Aspen emphysema Conference. This term became established and today 
refers to COPD as the designation of this growing health problem (Briscoe & Nash, 
1965).  
COPD can be classified with respect to both phenotype and disease severity. It is a 
heterogeneous disease process that varies greatly from person to person with 
respect to lung pathology, natural history of disease and comorbidity. A result of this 
heterogeneity is that different researchers have championed alternatively 
hypotheses about COPD development over the past four decades. The British 
hypothesis stated that the presence of cough and sputum was the key factor in 
   
  
14 | P a g e  
 
COPD (Anthonisen, 2005), and the Dutch hypothesis pointed to the presence of 
increased airways responsiveness (Vestbo & Prescott, 1998). Less widely known 
hypotheses stressed the part of genetic factors (the Swedish hypothesis) and the 
role of impaired repair processes in the development of emphysema (the American 
hypothesis) (Rennard, 1998). All these hypotheses probably have elements of truth 
since COPD disease manifests increased airways reactivity, a characteristic 
response to infections, abnormal cellular repair and development of complications or 
comorbid conditions.  
1.2 COPD FEATURES AND MECHANISMS 
 
1.2.1 COPD PATHOPHYSIOLOGY 
 
Chronic obstructive pulmonary disease is a common preventable and treatable 
disease though it is not curable. COPD is characterized by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases. The 
main site of airflow obstruction in COPD is the small airways (Hogg & Timens, 2009). 
Airflow limitation in COPD may result of three different pathological mechanisms. 1) 
Luminal obstruction with mucus and plasma exudate as a result of inflammation, 2) 
Emphysema as a results in expiratory collapse for two reasons: Disruption of 
alveolar attachments permits small airways to close on expiration due to lack of 
elastic support and loss of lung elastic recoil decreases the intraluminal pressure, 
which also predisposes to small airways to collapse , particularly with forced 
exhalation, 3) Thickening and fibrosis of small airways (Chronic Obstructive 
bronchiolitis) which is presumed to be due to the effect of chronic inflammation. 
Fibrosis occurs around small airways and is thought to be a main factor that 
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contributes to the irreversible airway narrowing that is the characteristics of this 
disease (Hogg et al, 2004).  
Chronic inflammation leads to the airways becoming narrowed, which reduces 
airflow. Cigarette smoke and other pollutants activate several inflammatory and 
structural cells of the lung to produce inflammatory and remodelling responses. An 
inflammatory cell plays a vital role in pathogenesis of COPD and is characterized by 
chronic inflammation throughout the airways, parenchyma and pulmonary 
vasculature. Macrophages, T lymphocytes (predominately CD8) and neutrophils are 
increased in various parts of the lung. Activated inflammatory cells release a variety 
of mediators including leukotriene B4 (LTB4) (Hill et al, 1999), Interleukin-8 
(Yamamoto et al, 1997), tumor necrosis factor-alpha (Keatings et al, 1996) and 
others capable of damaging lung structures or sustaining neutrophilic inflammation.  
In addition to inflammation, two other processes thought to be important in the 
pathogenesis of COPD are an imbalance of proteinases and anti-proteinases in the 
lung and oxidative stress. 
1.2.1.1 MUCUS HYPERSECRETION 
Epithelial cells in human lungs are the first anatomical barrier between the tissue and 
inhaled air which are exposed in the airways. The upper lining of epithelial cells in 
the airways prevents toxins, inhaled foreign particles, allergens intruding and 
disturbing the sub-epithelial cell layers of airway walls. Ciliated epithelial cells play a 
major role in expelling the inhaled particles and mucus out of the lung in to the 
esophagus, where these possibly harmful factors are digested or otherwise exported 
from the body (Nordgren et al, 2014). Under chronic inflammatory conditions, this 
mechanism is disturbed and results in a destruction of the epithelial cell layer, which 
results in the subsequent loss of function as a barrier between inhaled air and sub-
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epithelial tissue (Hessel et al, 2014).  
Role of Mucin: 
In normal airways, a thin layer of mucus covers the airway epithelium surface. 
Airway mucus is composed of 97 % water and 3 % solids (Wanner, 1996). Mucus 
maintains hydration and protects airways against toxic gases, inhaled pathogens via 
mucociliary clearance. Mucus transports antioxidants, antiproteases, antimicrobial 
substances by contributing to innate immune response but airway obstruction can be 
resulted due to abnormal mucus production. During such inflammatory conditions the 
epithelium that lines the airways becomes ironically inflamed leading to a breakdown 
in its integrity. Mucous glands become bigger, resulting in increased mucus 
secretion. The cilia that line the airways are destroyed and the ability of lung to 
remove mucus is impaired. Mucus hypersecretion results from an increase in mucin 
production & secretion from airway epithelial goblet cells and /or submucosal glands. 
Secreted mucins are high molecular weight 
glycoproteins synthesised in airway epithelial goblet cells and in mucus tubules of 
submucosal glands (Fahy & Dickey, 2010). The two main secreted airway mucins 
are MUC5AC and MUC5B (Fahy & Dickey, 2010; Rose & Veynow, 2006).  Increased 
mucin stores are generally found in airway epithelium of proximal (Innes et al, 2006 
& O’Donnel et al, 2004) and distal airways in COPD patients (Kim et al, 2008 & 
Saetta et al, 2000). Mucus hypersecretion in distal airways of COPD was further 
attested by the presence of mucus exudates obstructing airway lumens (Caramori et 
al, 2004 & Hogg et al, 2004). Many stimuli relevant to COPD induce mucin 
production in airway epithelial cells. One of them is cigarette smoke products like 
nicotine and acrolein (Borchers et al, 1998 & Gundavarapu et al, 2012). Cigarette 
smoke damages the airway epithelium leading to squamous metaplasia. This 
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abnormality is also seen in smokers without COPD, and likely does not contribute 
significantly to airflow obstruction. On a macroscopic level, epithelium layer thickness 
increases incrementally as disease severity worsens (Hogg et al, 2004).  
Mucous Hyperplasia: 
An important component of epithelial remodelling is mucous hyperplasia, a process 
in which mucus is overproduced in response to inflammatory signals (Williams et al, 
2006).  Mucous hyperplasia has been found in small airways of patients with COPD 
and significantly contributes to airflow obstruction (Hogg et al, 2004; Saetta, 2000 & 
Baraldo et al, 2003). This may develop from cigarette smoke exposure itself (Ebert & 
Terracio., 1975 & Deshmukh et al, 2005), acute and/or chronic viral infection 
(Holtzman et al, 2005), or inflammatory cell activation of mucin gene transcription 
(Burgel & Nadel, 2004). Chronic mucus hypersecretion accelerates lung function 
decline (Vestbo et al, 1996) and predisposes to hospitalization and infection 
(Prescott et al, 1995). Mucous metaplasia causes airflow obstruction by several 
mechanisms: increased mucus hypersecretion causing luminal occlusion, epithelial 
layer thickening encroaches on the airway lumen (James & Wenzel, 2007) and 
increased mucus alters surface tension of the airway, thereby predisposing it to 
expiratory collapse (Macklem et al, 1970).  
Neutrophils: 
Neutrophils are recruited in the airways of COPD patients (O'Donnell et al, 2004). 
Neutrophils may play multiple roles in mucus hypersecretion in COPD.  Neutrophil 
proteases induce rapid and potent mucin secretion when neutrophils are recruited in 
close contact with airway epithelial goblet cells (Agusti et al, 1998 & Takeyama et al, 
1998). Further, there is evidence of neutrophil elastase which induces mucin 
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synthesis in vitro in cultured airway epithelium cells (Shao & Nadel, 2005 & Kohri et 
al, 2002) and induces goblet cell metaplasia in vivo (Voynow et al, 2004). 
Histopathological evidence of mucus hypersecretion in proximal airways of COPD 
patients has been closely associated with symptoms of chronic cough and sputum 
production (Mullen et al 1985 & Saetta et al, 1997). Chronic cough and sputum 
production are frequently present in (ex) smokers with COPD (Burgel, 2012). The 
distal airways of 19 COPD patients were studied by Kim et al, reported that mucin 
stored in epithelium increased with increasing airflow limitation (2008). Hogg et al 
(2004) have shown that obstruction of distal airways with mucus exudates is a major 
& independent determinant of airflow limitation in COPD patients. Importantly, 
chronic cough and sputum production are associated with increased rates of COPD 
exacerbations (Burgel et al, 2009), more rapid decline in lung function (Vestbo et al, 
1996) and premature deaths (Ekberg-Aronsson et al, 2005).  
1.2.1.2 EMPHYSEMA 
Emphysema is a pathologic term defined as the abnormal permanent enlargement of 
airspaces by destruction of their walls and without obvious fibrosis (Piquette et al, 
2000). Two main sub-types exist: Centrilobular Emphysema (CLE) and Panlobular 
Emphysema (PLE). CLE affects the lobules around the central respiratory 
bronchioles (Leopold & Gough, 1957), and is the primary pathologic subtype 
associated with cigarette smoke induced Obstructive Pulmonary Disease (OPD). 
This pattern of emphysema is typically more prominent in upper lung zones (Heard, 
1958 & Thurlbeck 1963). PLE uniformly affects the entire secondary lobule (Wyatt et 
al, 1962). This subtype differs from CLE, as it is associated with α1-antitrypsin 
deficiency and is more prominent in the lower lung zones (Thurlbeck, 1963).   
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One reason of obstruction is due to emphysematous changes where there is loss of 
elastic fibers in the alveolar walls and subsequent destruction of the alveoli (Black et 
al, 2008 & Merrilees et al, 2008). The chronic and abnormal inflammatory process 
induced by tobacco smoking contributes to increased extracellular matrix 
degradation and promotes the structural changes in lung parenchyma. Because of 
remodelling and narrowing of small airways and destruction of the lung parenchyma 
(pulmonary emphysema) there is consequent loss of the alveolar attachments of the 
airways (Morjaria et al, 2010). This results in diminished lung recoil, higher 
resistance in flow, and closure of small airways at higher lung volumes during 
expiration, with consequent air trapping in the lung. This leads to the sensation of 
dyspnoea and decreased exercise tolerance. Both small airway remodelling and 
pulmonary emphysema result from chronic peripheral lung inflammation (Caramori et 
al, 2015). 
Alpha-Antitrypsin Deficiency (AAT): 
AAT deficiency is a genetic cause of Chronic Obstructive Pulmonary Disease (Kelly 
et al, 2010). AAT is synthesised and secreted mainly in the liver by hepatocytes 
(Eriksson et al, 1978 & Koj et al, 1978) and also secreted from macrophages 
(Mornex et al, 1986) and bronchial epithelial cells. AAT is released by liver in 
circulation gets to the lung parenchyma where it buffers any excess in neutrophil 
elastase activity. Deficiency of AAT leads to protease/Anti-proteases imbalance, 
particularly during increased elastase activity such as acute disease exacerbations 
or exposure to inhaled irritants (i.e., tobacco smoke). 
Proteinase and Anti-Proteinases Imbalance: 
Proteinases-anti proteinases imbalance may play a central role in the pathogenesis 
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of COPD (Hogg & Senior, 2002).  An important source of both proteinases and anti-
proteinases within the lung is the alveolar macrophage, which produces Matrix 
Metalloproteinases (MMP1, MMP9 and MMP12) important for airway inflammation 
and the development of Emphysema (Shapiro, 1999 & Mocchegiani et al, 2011). 
Macrophages are the most abundant cell type found in BALF of COPD patients 
(Macnee, 2005). Cytokines such as IL-1beta and tumor necrosis factor (TNF) play 
crucial role in pathology of COPD (Chung, 2001). Bronchial damage through 
inflammation which causes tissue damage could contribute to emphysema. Thus, it 
is important to examine expressions of proteinases and anti-proteinases induced by 
inflammatory cytokines (Wilson, 2001). 
1.2.1.3 FIBROSIS 
 
During injury and repair, the boundaries of the tissue disintegrate and the protective 
architecture of the extracellular matrix (ECM) is disturbed, thereby exposing cells to 
drastic changes in the mechanical environment. Under this mechanical imbalance 
cells are exposed to an overwhelming cocktail of cytokines, initially derived from 
damaged cells, inflammatory cells and myofibroblasts which drive tissue repair by 
secreting collagen and reorganizing the ECM (Gurtner et al, 2008 & Hinz, 2010). 
Fibrosis is characterized by the massive deposition of Extracellular Matrix (ECM) as 
a reactive process initiated to protect the tissue from injury. Fibrosis is associated 
with the overgrowth, hardening and scarring of tissues and is frequently observed in 
chronic diseases of the lung, liver, kidney and heart (Guarino et al, 2009 & Wynn, 
2008). 
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Fibroblasts and Myofibroblasts: 
Lung fibrosis is characterized by progressive and irreversible destruction of lung 
architecture, disruption of gas exchange and death from respiratory failure (Wynn 
2011). Fibroblasts and Myofibroblasts are the main cell types responsible for 
synthesis and secretion of the extracellular matrix (ECM) proteins and proteoglycans 
during tissue repair (Hinz et al, 2012, Klingberg et al, 2013). Fibroblasts are 
heterogeneous with respect to several phenotypic features. Under non-pathological 
condition, fibroblasts maintain homeostasis of the tissue (Powell et al, 1999 & Turner 
& Grose, 2010). Fibroblasts are spindle shaped cells found in stroma of tissues and 
during fibro-genesis, they get highly activated and possess the phenotypic 
characteristic of myofibroblasts. In adult tissue, myofibroblasts are activated by 
inflammation and are involved in maintaining the homeostasis and wound healing 
(Eckes et al, 2000, and Wynn, 2008). Myofibroblats express α-smooth muscle actin 
(α-SMA) and differ from fibroblasts by the presence of cytoplasmic bundles of 
contractile microfilaments or stress fibers, which are similar but not identical to those 
in smooth muscle cells (Desmouliere et al, 2003). They are also characterized by an 
increased proliferation, migratory ability, production of cytokines and greater capacity 
to produce interstitial matrix (Desmouliere et al, 2003 & Guarino et al, 2009). 
However, due to the inability of myofibroblasts to regenerate tissue, they often create 
collagenous and stiff scar. This scar tissue frequently disrupts the function of intact 
residual tissues and alters the biochemical and biophysical microenvironment turning 
neighboring cells into fibrotic and dysfunctional cells (Hinz, 2009). Therefore, 
deregulated activity of myofibroblasts results in impaired tissue function and even 
organ failure (Hinz, 2009 & McAnulty, 2007).  Myofibroblasts are prominent 
components of fibrosis in many tissues, including lungs (Schurch et al, 1998). 
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Myofibroblasts were originally believed to be generated by proliferation and 
activation of local fibroblasts (Barnes & Gorin, 2011 & Grillo, 1963). It has been 
considered, myofibroblasts can be derived from multiple sources (Abe et al, 2001 & 
Zeisberg et al, 2007). During pulmonary fibrosis, they are assumed to arise through 
trans-differentiation of resident pulmonary fibroblasts (Hashimoto et al, 2004). The 
circulating fibroblasts like cells which are derived from bone-marrow influx to the site 
of tissue injury are termed as ‘fibrocytes’ and possess fibroblast features (Abe et al, 
2001 & Phillips et al, 2004). Fibrocytes are systemic source of contractile 
myofibroblasts in various lesions in lung as well as in keloids, sclerodema and kidney 
(Abe et al, 2001). Similarly, in liver fibrosis bone marrow derived hepatic stellate cells 
(HSCs) appear to be source of myofibroblasts (Baba et al, 2004). Myofibroblasts 
may be the effector cells in fibro proliferative diseases such as idiopathic pulmonary 
fibrosis (IPF) and COPD as well as the stromal reaction occurring in lung cancer 
(Lofdahl et al, 2011, De Wever et al, 2008 & Hinz et al, 2012). However, IPF falls 
under the category of interstitial lung disease. The distinct characteristics of IPF is 
the scarring of lung tissue which gets thicken and harden, making more difficult for a 
person to breathe whereas the destruction of alveoli and fibrosis of airway walls are 
characteristics of COPD which leads to the enlargement of air spaces. The fibrotic 
alternations in COPD, structural changes are observed primarily in the small airways 
(<2mm in diameter), and the severity of the disease appears to be determined by the 
thickening of the wall of the small airways caused by the fibrosis and infiltration of 
inflammatory cells (Jeffery, 2004). Airflow limitation is caused by tissue remodeling 
including reorganization of the extracellular matrix (ECM). In COPD lung ECM is 
degraded in alveoli and there is excessive deposition of ECM (fibrosis) in bronchi 
and bronchioles (Hogg et al, 2004). The elevated expression of ECM proteins are 
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associated to increased number of myofibroblasts, The sub-epithelial fibrosis 
encountered in airways is caused by a deposition of extracellular matrix (ECM) 
proteins like tenascin-c (Tn-C), collagens, fibronectin (Fn) and proteoglycans (Jones 
& Jones, 2000). The central airways and alveolar lung parenchyma contain distinct 
fibroblast populations. They possess different morphology, proliferation and ECM 
production (Kotaru et al, 2006 & Pechkovsky et al, 2010). This distinction is 
important to consider in COPD, as the ECM turnover is different in bronchi and 
alveoli. A study by (Hallgren et al, 2010) found differences in fibroblasts from COPD 
and control subjects. A lower potential proliferation was observed in COPD subjects 
compared to control subjects. The reason for this lower proliferation of fibroblast can 
be cigarette smoke (Nobukuni et al, 2002). Cigarette smoke can induce inflammation 
and directly damage the lungs (Wright et al, 1992). It is believed that this 
inflammation can lead to COPD. On the other hand, studies suggest that the tissue 
repair capacity of lung fibroblasts, which are responsible for the extracellular matrix 
regeneration and maintenance, appears to be decreased in COPD. One piece of 
evidence supporting the impaired repair theory is the reduced proliferation of 
fibroblasts seen in the patients with COPD compared to patients with normal lung 
function, despite a comparable smoking history (Holz et al, 2004 & Muller et al, 
2006).  
Airway smooth Muscle cells: 
Airway smooth muscle cells have been believed to be a bystander of chronic 
inflammation in the airways of lung. In asthmatic patients, airway smooth muscle 
cells plays an important role in modulating the inflammatory response, which is 
characterized by thickening of airway walls and in COPD patients it has been 
assumed this to be a result of chronic inflammation. (Postma et al, 2014, Meurs et al, 
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2013 & Morgan et al, 2014). Studies have found airway smooth muscle mass to be 
increased in COPD (Bosken et al, 1990 & Kuwano et al, 1993). Chronic airflow 
inflammation from cigarette smoke causes constriction and hypertrophy of even 
normal airway smooth muscle (Baraldo et al, 2003). This serves to increase airway 
wall thickness and therefore cause greater luminal narrowing. In addition, the same 
degree of smooth muscle contraction in a thickened airway causes considerably 
greater airways resistance than in normal airways (Lambert et al, 1993). Several 
investigators have found direct correlations with the degree of smooth muscle mass 
and airflow obstruction in COPD (Hogg et al, 2004 & Finkelstein et al, 1995), 
supporting notion that smooth muscle hypertrophy not only is a significant pathologic 
finding but also that it contribute to the pathogenesis of COPD.  
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FIGURE 1.1 PATHOPHYSIOLOGY OF COPD 
Overview of the pathological processes that can take place in COPD.  Pathology 1: Fibrosis 
occurs causing thickening of the respiratory membrane where O2 diffuses into the blood.  It 
is not yet fully understood why fibrosis occurs or where the fibroblasts come from, and this 
area is one of the key aims of this study.  Pathology 2: Alveolar wall destruction is a cause of 
emphysema and linked with neutrophil and cytotoxic T cell activity.  Pathology 3: Mucus over 
secretion is a key cause of obstruction in COPD and onset by monocyte and neutrophil 
activity.  Adapted from Nat Revs Immunology Barnes 2008. 
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1.2.2 COPD EXACERBATIONS 
 
COPD is characterized by episodic increases in respiratory symptoms, which are 
called exacerbations. The GOLD guidelines define COPD exacerbations as "an 
acute event characterized by a worsening of patient’s normal day to day variations 
and leads to a change in medications (GOLD, 2011). Figure 1.2 shows the causes 
and risk factors for COPD exacerbation which include air pollution and most 
commonly bacterial and viral infection (GOLD, 2011, Peacock et al, 2011 & Sethi & 
Murphy, 2008). Bronchoscopic studies have shown that at least 50% of patients 
have bacteria in their lower airways during exacerbations of COPD (Sethi & Murphy 
2008). During exacerbations precipitants worsen the bronchial inflammation, 
characteristic of stable COPD as evidenced by a rise in bronchial neutrophils and 
sign of oxidative stress (Drost et al, 2005 & Qiu et al, 2003). Oxidative stress is a key 
factor in the development of airway inflammation in COPD. Patients with severe 
exacerbations who needed hospital admission or assisted ventilation have evidence 
of increased large airway interleukin-8 (IL-8) levels and increased oxidative stress 
(Drost et al, 2005). Systemic inflammation increases when exacerbation is 
associated with bacterial and viral infection (Wedzicha et al, 2000). Several 
inflammatory markers increase at exacerbation, such as plasma fibrinogen and CRP 
that have been linked to increased cardiovascular risk. Respiratory infections have 
been associated with increased cardiac events (Smeeth et al, 2004) and thus COPD 
exacerbation if triggered by an infection, might increase cardiac morbidity. 
Inflammatory responses during COPD exacerbations result in cascades of increased 
lung inflammatory cell numbers and inflammatory cell mediator’s release, enhancing 
the pathological process associated with lung function loss (Anzueto, 2010). A 
modest increase in the number of neutrophils, lymphocytes and eosinophils are seen 
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in the airways during exacerbations. Also, the airway inflammatory responses during 
COPD exacerbations cause airway oedema, bronchospasm, and increased sputum 
production, leading to worsening airflow limitation and development of dynamic 
hyperinflation (O’Donnell & Parker, 2006).  So, markers of inflammation play a major 
role for assessment and thus investigation of sputum in chronic lung disease is 
focused on inflammatory mediators (Mayer-Hamlett et al, 2007, Roy et al, 2009 & 
Schmitt-Grohe et al, 2002). 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.2 COPD EXACERBATIONS 
Bacteria, viruses, pollutants trigger and cause associated symptoms leading to 
pathophysiological changes. Adapted from Lancet Wedzicha and Seemungal, 2007. 
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1.2.3 RISK FACTORS IN COPD 
 
The role of cigarette smoke, exposure to outdoor and indoor pollutants, history of 
pulmonary tuberculosis (TB), asthma, and genetic factors are recognized as 
potential factors contributing to the development of COPD.  
Cigarette smoke: 
Cigarette smoke is the most common risk factors in COPD. Cigarette smoke 
contains harmful toxins that affect lung functionality. Toxins that are inhaled directly 
into the lungs over prolonged periods of time can lead to severe lung irritation, 
triggering the onset of COPD and eventually leads to inflammation and degradation 
in the lung (Brody and Spira, 2006).  
Cigarette smoke causes an inflammatory process in the central airways, peripheral 
airways and lung parenchyma which is present even in smokers with normal lung 
function (Saetta, 1999). Bronchial biopsies of smokers have shown chronic 
inflammatory changes, with increased numbers of T-lymphocytes and macrophages 
in lung and structural remodeling resulting from repeated injury and repair (Saetta et 
al, 1993). It has been reported in studies that approximately 50% of smokers 
eventually develop COPD (GOLD 2008 and Lundback et al, 2003).  
Indoor and outdoor air pollutants: 
Globally, in the low income countries exposure to indoor air pollution is responsible 
for causing the COPD burden. According to world health organization (WHO), almost 
3 billion people worldwide use biomass and coal as their main source of energy for 
cooking, heating and other household needs. Biomass fuel used by women for 
cooking account for high prevalence of COPD among non-smoking women in parts 
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of middle east, Africa and Asia.  
Moreover, health risks from air pollution are greatest among elderly, children and 
those with chronic health conditions like asthma and COPD. The long term exposure 
to outdoor air pollution is thought to increase the risk of developing COPD. Also, the 
exposure to particulate matter air pollution makes COPD symptoms worse, resulting 
in an increased risk of death in people who have existing COPD. WHO estimates 
that urban air pollution causes 1 % cases of COPD in high income countries and 2 % 
in nations of low and middle income.  
Pulmonary Tuberculosis: 
As respiratory system is the most common site of active disease, Pulmonary TB may 
be the strongest risk factor in COPD in a TB endemic area (Hersh et al, 2007). 
Tuberculosis is characterized of chronic cascous granulomatous inflammation 
resulting in devastating tissue damage if left untreated (Elkingto et al, 2011). As the 
most common site of involvement, pulmonary TB can cause permanent obstruction 
or restrictive pulmonary function impairment, which in turn can contribute to the 
pathogenesis of COPD (Hnizdo et al, 2000, Chung et al, 2011 & Pasipanodya et al, 
2007).   
These comorbidities contribute to reduced health status, increased healthcare 
utilization and hospital admission and mortality (Decramer et al, 2012).  
Asthma: 
 
Asthma has been recognized to be a risk factor for developing COPD (Silva et al, 
2004). More than 40% of patients with COPD report the history of asthma (Hersh et 
al, 2007). There are some striking similarities and differences in pattern of 
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inflammation between asthma and COPD. COPD affects both airways and 
parenchyma whereas asthma affects only the larger conducting airways (Barnes, 
2000 & Jefferey, 2000). Both asthma and COPD are characterized by airway 
obstruction, which is variable and reversible in asthma but is progressive and largely 
irreversible in COPD. Despite differences in the casual agents, both COPD and 
asthma exhibit various degrees of inflammatory changes, narrowing of airways 
leading to airflow limitation and structural alteration of the pulmonary airways and 
vessels (Postma & Timens, 2006). In asthma, the deposition of collagen results in 
thickening of basement membrane termed as sub epithelial fibrosis whereas in 
COPD, collagen deposition is mainly around the airways termed as peribronchiolar 
fibrosis. Infiltrations of inflammatory cells in airways such as mast cells; granulocytes 
and macrophages show marked differences in both diseases. Mast cells plays a key 
role in asthma through the release of broncho-constrictors like histamines, release 
lipid mediators leukotriene (LT)C4, LTD4, LTE4 with prostaglandin D2 and also 
release cytokines linked to allergic inflammation, including interleukin (IL)-4, IL-5 and 
IL-13 (Galli et al, 2005). Asthma is most frequently diagnosed during childhood and 
is associated with atopy and eosinophilic inflammation, COPD is usually diagnosed 
during middle or later life and is associated with neutrophilic inflammation (Barnes, 
2000). These reflect the differences in secretion of different chemotactic factors in 
these diseases. CC-chemokine Ligand (CCL) 11 is released mainly in epithelial cells 
in asthma. COPD shows the increased numbers of neutrophils in sputum along with 
the production of CXC-chemokine ligand (CXCL) 1, (CXCL) 8 in neutrophils and 
correlates with disease severity in COPD and asthma (Keatings et al, 1996). 
Macrophages are observed in both diseases. However, COPD shows far greater 
numbers of macrophages than in asthma. Macrophages amplify the airway 
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inflammation by releasing chemokines that attract neutrophils, monocytes, T-cells 
and proteases mainly MMP9 (Barnes, 2004). The pattern of inflammatory cells found 
in the respiratory tract therefore differs between COPD and asthmatic patients. 
Inhaled corticosteroids are effective against the inflammation in asthma but largely 
ineffective against the COPD inflammation (Haatela et al, 1991, Jefferry et al, 1992 & 
Keatings et al, 1997). Although asthma and COPD are two different diseases 
differential diagnosis is sometimes difficult and may be impossible in some older 
patients (Guerra, 2004), as response to pharmacologic treatment leads to 
reversibility of pulmonary obstruction in asthma and may decrease over time in some 
patients with long standing asthma, to the point of irreversible or only partly 
reversible airway obstruction. 
1.3  DIAGNOSIS 
 
Clinical Assessment: 
A detailed medical history of a patients with symptoms suggestive of COPD should 
include exposure to risk factors (e.g., smoking and occupational or environmental 
exposures), family history of COPD or other chronic respiratory disease, patterns of 
symptoms, history of exacerbations, presence of comorbidities, medical treatments 
and patients quality of life. Diagnosis of COPD is based on a history of exposure to 
risk factors and the presence of airflow limitation that is not fully reversible, with or 
without the presence of symptoms. Since the early stages of COPD may manifest as 
chronic cough and sputum production, they may be present even in smokers without 
airflow limitation. 
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1.3.1 SPIROMETRY 
 
Breathing test known as spirometry can be performed using a machine called a 
spirometer. This breathing test can determine the severity of lung function 
impairment. For the diagnosis and assessment of COPD, spirometry is the gold 
standard as it is the most reproducible, standardized and objective way of measuring 
airflow limitation. The important parameter measured during spirometry is called the 
Forced Expiratory Volume in 1 second and is abbreviated as FEV1, this is the 
volume of air that can forcibly be breathed out in 1 second following a deep breath 
inwards.  The Global Initiative for Chronic Obstructive Lung disease (GOLD) has 
introduced a five stage classification for the severity of COPD based on 
measurements of air flow limitation during forced expiration. Each stage is 
determined by the volume of air that can be forcibly exhaled in one second (FEV1) 
and by the ratio of FEV1 to the forced vital capacity (FVC) (Fig 1.3). 
 
 
FIGURE 1.3 SPIROGRAM: RESPIRATORY MOVEMENT BY SPIROMETER. 
Classification of severity of Airflow limitation in COPD according to the GOLD criteria 
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 Table 1 Classification based on post bronchodilator lung function 
GOLD 1 (mild) FEV₁/FVC <0.70 and FEV₁ ≥ 80% predicted 
GOLD 2 
(moderate) 
FEV₁/FVC <0.70 and 80% > FEV₁ ≥ 50% predicted 
GOLD 3 (severe) FEV₁/FVC <0.70 and 50% > FEV₁≥ 30% predicted 
GOLD 4 (very 
severe) 
FEV₁ <50% predicted plus chronic respiratory failure 
 
Table 1 shows people with an FEV₁/FVC ≥0.70 and respiratory symptoms of chronic 
cough and sputum production are no longer included as a COPD stage (formerly 
GOLD stage 0). Patients with an FEV₁/FVC≥0.70 but an FVC < 80% predicted meet 
spirometric criteria for restrictive process. Although this is not regarded as COPD, 
patients might present with several symptoms to these seen in COPD and these 
patients have an increased risk of deaths. 
 
1.3.2 ASSESSMENT BY IMAGING 
 
Airflow limitation in COPD is due to both small airway disease (obstructive bronchitis) 
and parenchyma destruction (emphysema), the relative contributions of which vary 
among patients. Thin-section CT has been used to quantify emphysema by detecting 
low-attenuation areas. Theoretically, thin-section CT depict the dimensions of 
airways as small as  ̴1 to 2 mm in inner diameter, suggesting that CT can be used to 
evaluate airway dimensions in a variety of disease (Coxson & Rogers, 2005). 
However, airflow limitation evaluated by FEV1 does not show a good correlation with 
the severity of emphysema as evaluated by CT (Baldi et al, 2001 & Omori et al, 
2008) because small airway disease appears to contribute significantly to airflow 
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limitation (Hogg, 2006). Scintigraphic approaches may be used to assess COPD and 
to provide functional imaging. Ultrafine ¹³³Xe gas particles are being used for 
ventilation scintigraphy including single photon emission CT (SPECT) (Magnant et 
al, 2006). 
Early stages of COPD can be confirmed using spirometry but other morbidities like 
lung cancer should also be taken into consideration. As tobacco smoking is one of 
the major risk factor in development of COPD, it is also associated with developing 
lung cancer (Bach & Ginsberg, 2002). The tobacco smoke stimulates both local and 
systemic inflammation and this inflammation play a casual role in both COPD and 
lung cancer (Barreiro, 2008). COPD diagnosis has been associated with a higher 
rate of lung cancer (Skillrud et al, 1986, Maninno et al, 2003 & Tockman et al, 1987), 
on the other hand several studies have shown that a common cause of death 
between those affected with COPD is lung cancer, mostly when COPD is mild and 
moderate (Manini et al, 2003). Skillrud et al and Tockman et al (2003), show that 
airway obstruction is associated with an increment 4 to 6 times in the risk to develop 
lung cancer, independently of tobacco smoking history. So for detection, differential 
diagnosis, staging and follow up of lung cancer imaging examinations like Computed 
Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission 
Computed Tomography (PET-CT) play an eminent role.  
 
1.3.3 ASSESSMENT OF AIRWAYS 
 
Numbers of cytokines and chemokines are secreted in both asthma and COPD and 
are regulated by the transcription factor nuclear factor-ƙB, which is activated in 
airway epithelial cells and macrophages in both diseases and may have an important 
role in amplifying airway inflammation. Quantification and characterisation of 
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inflammatory changes are important assessments in diagnosis of COPD. These 
assessments can be performed by invasive and non-invasive methods. Bronchial 
biopsies, broncho alveolar lavage (BAL) or examination of surgical specimens are 
meant to be invasive methods whereas spontaneous and induced sputum is 
described as non-invasive. A different profile of inflammatory cells is obtained 
depending on the compartment of the lung examined by the techniques. The airway 
wall can be examined using bronchial biopsies and the peripheral airways using BAL 
(Maestrelli et al, 1995) whereas sputum analysis is performed for the examination of 
lumen of the airways (Alexis et al, 2000). Bronchial biopsies from asthmatic subjects 
reveal an infiltration of eosinophils, activated mucosal mast cells at the airway 
surface and activated T-cells whereas in COPD there is no evidence of mast cell 
activation but there is infiltration of T-cells and increased numbers of neutrophils, 
particularly in the airway lumen (Hogg, 2004). The release of mediators like 
histamine by mast cells in asthma may account for the variable bronchoconstriction 
as they are triggered by environmental allergens. On other hand mast cells do not 
seem to play a role in COPD which may explain the lack of variable 
bronchoconstriction. Also, presence of mast cells in airway smooth muscle is linked 
to airway hyper responsiveness (AHR) in asthma (Brightling et al, 2002). Several 
studies have suggested that asthma and AHR are important risk factors contributing 
to an increased rate of decline in FEV1 and thus to the development of COPD 
(Lange et al, 1998, Peat et al, 1987, Shernill et al, 2003, & Fletcher et al, 1976). The 
18 years follow up study carried out by Peat et al found asthmatic subjects having 
greater rate of decline in FEV1 and a lower baseline lung function than in non-
asthmatics (1987). Approximately 10% of patients with COPD have reversibility in 
lung function as assessed by forced expiratory volume in one second (FEV1), and 
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therefore behave more like asthmatics. These patients frequently have eosinophils in 
their sputum, an increase in exhaled nitric oxide and respond better to corticosteroid 
treatment, all of which are feature of asthma (Papi et al, 2000 & Brightling et al, 
2005).  
 
1.3.4 DIFFERENTIAL DIAGNOSIS 
 
SPUTUM ANALYSIS: 
Analysis of induced or spontaneous sputum has contributed to the identification of 
smokers susceptible to developing COPD, to the characterisation of the 
inflammatory process during exacerbations and to the effects of intervention with 
anti-inflammatory drugs or by smoking cessation. Abnormal inflammatory response 
of the lung can be driven by external drivers like cigarette smoke or noxious particles 
or gases. In COPD, the most common sputum changes in neutrophilia are increased 
products of neutrophil activation, including proteases, myeloperoxidase and elastase 
(Chung 2001, Kim & Nadel, 2004). Induced sputum shows a characteristic increase 
in the proportion of neutrophils that is much greater in patients with COPD than in 
smokers without obstruction (Stanescu et al, 1996). This suggests that sputum 
neutrophils or their products may be used as early markers of the manifestation of 
COPD.  A study by Sunner et al ( 2013) identified sputum neutrophils and phlegm as 
important factors associated with cough in COPD patients, suggesting that 
molecules that target neutrophils (Barnes, 2007) represent interesting therapies to 
reduce mucus hypersecretion (Burgel & Wedzicha, 2013).  
COPD is associated with other comorbid conditions, and patients who are admitted 
to hospital are more likely to have associated comorbid conditions such as ischaemic 
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heart disease, pneumonia and diabetes than patients without diagnosis of COPD. 
Pulmonary embolism also contributes to exacerbations, as approximately 25% of 
patients hospitalized for an acute exacerbation of COPD may have a pulmonary 
embolism (Rizkallah et al, 2009). 
1.4 EPITHELIAL TO MESENCHYMAL TRANSITION 
 
Respiration involves phasic movement of air through the conducting airways in and 
out of the gas-exchange portion of the lung i.e., the respiratory bronchioles, alveolar 
ducts, alveolar sacs and alveoli. Alveoli are microscopic thin- walled sacs that 
facilitate the exchange of the gases between the inspired air and the capillaries in 
the alveolar wall (Burri, 1997). The alveolar wall in the adult lung consists of a narrow 
connective tissue core that contains fibroblasts, pericytes and capillary endothelial 
cells and extracellular matrix components, most importantly those comprising the 
elastic fibres. The alveolar epithelium contains two main types of cells:  
1) Type 1: large flattened cells (95% of the total alveolar area) which present a very 
thin diffusion barrier for gases. They are connected to each other by tight junctions 
(Crapo et al, 1982). 
2) Type 2: (making up 5% of the total alveolar area, but 60% of total number of 
cells). These cells secrete 'surfactant' which decreases the surface tension between 
the thin alveolar walls, and stops alveoli collapsing when one breathes out, these 
cells are connected by tight junctions (Perez-Gil & Weaver, 2010). 
Epithelial to mesenchymal transition is a biological process that allows a polarized 
epithelial cell, which normally interacts with basement membrane via its basal 
surfaces, to undergo multiple biochemical changes that enable it to assume a 
mesenchymal cell phenotype, which includes enhanced migratory capacity, 
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invasiveness, elevated resistance apoptosis and greatly increased production of 
ECM components. EMTs are encountered in three distinct biological settings that 
carry very different functional consequences. 
Type 1 EMT: EMT during implantation, embryo development and organ development 
In embryogenesis, the initiation of placenta formation and implantation of embryo 
both processes are associated with EMT. A fertilized egg undergoes gastrulation. 
The first step is the formation of primitive streak which is generated in the epiblast 
layer (Hay, 1990). The epithelial like cells of the epiblast undergo programmed 
changes by specific expression of proteins associated with cell migration and 
differentiation (Thiery & Sleeman, 2006). This primitive streak generates the 
mesendoderm, which separates to form mesoderm and endoderm via an EMT by 
replacing hypoblasts cells, which either undergo apoptosis or contribute to the 
mesoderm layer via an EMT (Hay, 1995). Also, during embryonic development, a 
neural crest cells which expresses genes are formed by epithelial cells of the 
neuroectoderm and subsequently undergo EMT (Duband & Thiery, 1992). As a 
result, the cells become motile and disperse to form different parts of embryo by 
further differentiation. Hence, EMT programs are deployed during several 
subsequent phases of embryogenesis which shows involvement in later stages of 
organ development (Kalluri & Weinberg, 2009) 
Type 2 EMT: EMT associated with tissue regeneration and organ fibrosis 
In type 2, organ fibrosis in epithelial tissues is mediated by inflammatory cells and 
fibroblasts. EMT give rise to myofibroblast from epithelia to heal injured tissues, if the 
injury is mild or acute, the healing process is regarded as reparative fibrosis, but in 
ongoing inflammation, abnormal formation of myofibroblast cause progressive 
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fibrosis, therefore leading to organ parenchymal destruction by excessive deposition 
of extra cellular matrix (ECM) (Tenakoon, et al, 2016). The EMT knowledge has 
been accumulated using human pathological tissues and experimental animal 
models. The study of transgenic mice bearing germ line reporter genes whose 
expression was driven by epithelial-cell-specific promoters where evidence of 
formation of fibroblast from epithelial cells by EMT. In kidney fibrosis, myofibroblast 
are the main source of excessive ECM deposition. They are derived from renal 
epithelia/endothelia, interstitial fibroblastic cells or mesenchymal pericytes. EMT 
process from renal epithelia is regarded as the important pathway leading to 
formation of interstitial myofibroblast in diseased kidneys at advanced stages (Strutz, 
et al, 1995, Okado et al, 1997 & Rastaldi et al, 2002). Thus, "Type 2" programs 
begins as a part of a repair associated event that normally generates fibroblasts and 
other related cells in order to reconstruct tissues following trauma and inflammatory 
injury. Mainly wound healing, tissue regeneration and organ fibrosis are included. 
Though studies have shown EMT play a role in pulmonary fibrosis (PF) but its’s 
aetiology is still unclear. In COPD, EMT type 2 could be responsible for destruction 
of small airways whereas in PF it leads to scarring of lung tissues and PF being the 
restrictive disease our aim here is to identify role of EMT in COPD (obstructive 
disease) where smoking plays an important risk factor in causing it. 
Type 3 EMT: EMT associated with cancer progression and metastasis 
"Type 3" EMTs occur in neoplastic cells that have previously undergone epigenetic 
changes specifically in the genes that favour clonal outgrowth and the development 
of localised tumors (Kalluri & Weinberg, 2009). Excessive epithelial cell proliferation 
and angiogenesis are hallmarks of the initiation and early growth of primary epithelial 
cancers (Hanahan & Weinberg, 2000). Many mouse studies and cell culture 
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experiments have demonstrated that carcinoma cells can acquire a mesenchymal 
phenotype and express mesenchymal markers such as α-SMA (smooth muscle 
actin), FSP1 (fibroblast specific protein-1), vimentin and desmin (Yang & Weinberg, 
2008). The involvement of epithelial carcinoma cells in primary nodules transitioning 
to metastatic tumour cells in order to migrate through blood stream and in some 
cases, form secondary nodules in distant metastatic sites by mesenchymal epithelial 
transition (MET) (Zeisberg et al, 2005). 
1.4.1 EPITHELIAL MESENCHYMAL TRANSITION AND COPD 
Epithelial mesenchymal transition (EMT) has been well described in lung 
embryogenesis (Lee et al, 2006), metastatic malignant disease (Bjornland et al, 
1999) and as a part of the repair process following tissue injury in renal disease 
(Yanez Mo et al, 2003). EMT has been recognized in the human lungs and airways 
during and after lung injury (Willis et al, 2006, Ward et al, 2005 & Hackett et al, 
2009). Active EMT is indicated by the degradation of underlying epithelial cells into 
mesenchymal cells with migratory potential, such that they move away from the 
epithelium in which they origin into deeper tissue (Kalluri et al, 2003 & Rabe et al, 
2007). In COPD there can be both types of airway disease like chronic bronchitis 
and destruction of lung parenchyma (Emphysema) (Barnes et al, 2003). One of the 
features of chronic airway disease including COPD is airway remodelling (Nakuno et 
al, 2002 & Chung et al, 2006). Remodelling involves the differentiation of airway 
epithelial cells to mesenchymal phenotype, with subsequent migration through 
reticular basement membrane (Rbm) to the subepithelial lamina propria, a process 
termed as epithelial mesenchymal transition (Jeffery, 2004 & Willis et al, 2006). In 
addition to being structural cells of the lung, airway epithelial cells are mediator 
producing cells that become very active in COPD. Epithelial cells are activated by 
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cigarette smoke to produce inflammatory mediators, including TNF-α and IL-8 and 
also important source of transforming growth factor (TGF)-β, which induces local 
fibrosis. It is proposed that in COPD airway epithelium is damaged and/or activated 
by irritants such as cigarette smoke constituents, and this stimulates the deposition 
of collagen from myofibroblasts in the lamina propia (Sohal et al, 2010). The sub-
epithelial reticular basement membrane (Rbm) is variably thickened and markedly 
fragmented with clefts or elongated spaces within it. These elongated clefts in COPD 
contain cells. These cells positively express the mesenchymal markers S100A4, 
vimentin and MMP (Sohal, et al, 2011).  
 
FIGURE 1.4 EPITHELIAL MESENCHYMAL TRANSITION AND FIBROSIS 
During organ fibrosis (a), different types of inflammatory cells and resident fibroblasts 
(myofibroblasts) are generated which results in disruption and degradation of basement 
membrane (b). The epithelial cells lose polarity and either undergoes apoptosis or EMT (c). 
Adapted from (Kalluri and Weinberg, 2009). 
 
Cells undergoing EMT have been characterised in a range of tissues including renal, 
heart and liver fibrotic conditions (Zeisberg et al, 2007 & Zeisberg et al, 2008). It is 
useful to characterise biomarkers associated with EMT to both characterise the 
mechanisms of how it occurs, and to be able to monitor and grade the severity of the 
a b c 
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condition. The following proteins have been linked with the structural changes of the 
cells including Vimentin expression, S100A4 and αsmooth muscle actin each serving 
an important role during EMT. 
Vimentin serves to support intracellular structures in the cytosol of the cell.  It is 
accepted that vimentin is a cytoskeletal component supporting cellular integrity.  
Typically, vimentin is expressed in mesenchymal cells. α-smooth muscle actin is 
another typical marker of myofibroblast formation and is involved with cell motility 
and movement; it’s expression has been linked with fibroblast contractile activity and 
is upregulated by TGFß expression (Boris et al, 2001). 
1.4.2 THE ROLE OF S100A4 
 
S100A4 has been identified as a protein linked with a range of cellular functions such 
as cell cycle progression and differentiation including EMT.  The S100 gene family is 
the largest sub family of the calcium-binding proteins (Donato, 2001). S100A4 is 
calcium binding 101 amino acid polypeptide; upon calcium binding S100A4 undergo 
a confrontational change in the canonical EF-hand resulting in the exposure of a 
hydrophobic binding pocket formed by helics’ 3, 4, the hinge region (loop 2) and the 
C-terminal coil region (Figure 1.5 Garrett et al, 2006), thus allowing the protein to 
interact with different protein targets thereby explaining the broad range of 
intracellular and extracellular functions. Intracellular functions include regulation of 
cell cycle, cell growth, smooth muscle cell migration (SMC), phosphorylation and 
regulation of transcriptional factors. Extracellular function includes binding to cell 
surface receptors such as the receptor for advanced glycation end products (RAGE) 
and Toll-like receptors (TLRs) (Heizmann et al, 2002 & Donato, 2003). The 
interaction with non-muscle myosin proteins are well established and has been 
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demonstrated that metastasis-associated cellular motility is coupled to S100a4-NllA 
interaction (Li & Bresnick 2006 & Garrett et al, 2006). 
S100A4 is also known as metastatin (MtS1), fibroblast specific protein (FSP) 1, 
calcium binding protein placental homolog (APL1) and Calvasculin. The evidence 
connecting S100A4 and EMT comes from studies on renal fibrosis, in which S100A4 
was identified as a FSP and renamed FSP1 (Strutz et al, 1995).  
 
FIGURE 1.5 STRUCTURE OF S100A4-NONMUSCLE MYOSIN IIA INTERACTION 
Nonmuscle myosin llA complex structure of S100A4 with subunits A (Green) and B (Blue) 
are shown along with the two-fold symmetry axis of the 45-residue long dimer. Yellow 
peptides (residues 1893-1913), orange (residues 1914-1935) and Ca+2 ions are grey. 
(Adapted from Kiss et al, 2012). 
Immunohistochemical analysis of human cancers shows significant S100A4 
expression in breast, pancreatic, prostate, gall bladder, oesophageal, gastric, lung 
and thyroid carcinomas (Hefman et al, 2005). In these cancers, S100A4 expression 
is found at elevated levels compared with normal tissue suggesting that enhanced 
S100A4 contributes to manifestation of a metastatic phenotype.  
With relevance to the current study, S100A4 acts as a key player in EMT induction 
by regulation of E-cadherin, β-catenin, Snail/Slug, matrix-metalloproteinases (MMPs) 
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and nuclear factor-ƙB pathways (Keirsebilck et al, 1998, Brabletz et al, 2005, Stein et 
al, 2006, Moody et al 2005 & Grotterod et al, 2010). It is a prototypical fibroblast 
marker detecting EMT in breast cancer and fibrogenesis (Xue et al, 2003 & Iwano et 
al, 2002). In tissue fibrosis, most epithelial cells undergoing type 2 EMT express 
FSP1 early in transition to fibroblasts (Iwano et al, 2002). The pathological changes 
in the COPD are triggered by a chronic inflammation in lungs. Structural changes in 
pulmonary vascular remodelling include media hypertrophy, thickening of the intima 
with reduction of the lumen diameter and muscularization of small non-muscular 
arterioles (Barbere et al, 2004) and also the vasculature remodelling of lungs (in 
mice and humans) linked with cigarette smoking (Reimann et al, 2015). S100A4 
plays a major role in the smooth muscle cells (SMC) migration and proliferation 
which is thought to be depended upon an autocrine or paracrine stimulation of the 
RAGE receptor (Lawrie et al, 2005). 
Given the close association of S100A4 with EMT and EMT being a growing interest 
in COPD pathology, this study aims to investigate the expression of S100A4 in 
COPD lung tissue. 
1.5 CURRENT TREATMENTS 
 
Bronchodilation is the cornerstone of pharmaceutical treatment of COPD symptoms. 
Bronchodilators improve respiratory function, mainly by reducing the patient’s hyper 
inflated state as COPD progresses, thereby improving symptoms like breathlessness 
and poor exercise capacity (Schermer et al, 2007, Appleton et al, 2006 & Van Noord 
et al, 2006). The GOLD guidelines have recommended a stepwise approach for 
management of COPD with bronchodilators as mainstay for the treatment. 
Bronchodilators help open the airways. Bronchodilator medication can be short or 
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long acting. Three long-acting inhaled bronchodilators in COPD have been 
approved: Tiotropium, Formoterol and Salmeterol. Currently available 
bronchodilators for COPD are categorized in three classes: anticholinergics, β2-
sympathomimetic agonists and methylxanthines. As anticholinergics and β2-agonists 
both are equally effective, so GOLD guidelines do not have distinguished any 
difference. Impaired lung function in COPD is caused by structural narrowing of the 
airways, combined with the effects of cholinergic vagal broncholonstrictive tone and 
decreased lung elastic recoil (Gross et al, 1989 & Barnes, 1999). Bronchodilators 
improve the airflow limitation observed in patients with COPD by producing airway 
smooth-muscle relaxation, although β2-agonists and anticholinergics achieve this 
effect through different mechanisms. Anticholinergic bronchodilators (particularly 
Tiotropium) produce relaxation of airway smooth muscle through antagonism of 
acetycholine at M3-muscurinic receptors on airway smooth muscle (Barnes, 1995), 
whereas β2-agonists induce bronchodilation through stimulation of β2-receptors, 
leading to an increase in cyclic adenosine monophosphate. 
The differences in mechanisms between these two classes of inhaled 
bronchodilators are reflected in the relative utility of each for the management of 
COPD. Short acting β2-agonists, such as salbuterol, have a more rapid onset but 
shorter duration of action than anticholinergics and thus are commonly prescribed as 
"rescue" medication to help relieve acute bronchospasm. Inhaled anticholinergic 
medications, such as ipratropium, have a slower onset and slightly longer duration of 
action. One consequence of the differences in their modes of action is that the 
effects of combining anticholinergic and β2-agonists bronchodilators are additive, 
providing greater efficacy than either agent alone (Combinant Aerosol study group, 
1994).  
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1.5.1 INHALED CORTICOSTEROIDS (ICS) 
 
In asthma and COPD, inhaled corticosteroid (ICS) is commonly given as 
combination inhalers with long acting ß2-agonists (LABA). ICS are recommended 
anti-inflammatory treatment for COPD patients with a forced expiratory volume in 1 
second (FEV1) of less than 60% predicted and who are prone to frequent 
exacerbations. Inhaled corticosteroids are highly effective in asthma, but only offer 
modest help in COPD patients (Keatings et al, 1997). Both diseases involve 
inflammation of the respiratory tract, but the nature of the inflammation differs, 
indicating that different regulatory mechanisms are likely to be involved. 
Patients with asthma have a specific pattern of inflammation in the airways that is 
characterized by degranulated mast cells, infiltration of eosinophils and increased 
number of activated T helper cells (TH2 cells). Suppression of this inflammation by 
corticosteroids controls and prevents these symptoms in the vast majority of 
patients. There is increasing evidence that structural cells of the airways such as 
epithelial cells, airway smooth muscle cells, endothelial cells and fibroblasts are 
major source of inflammatory mediators in asthma. Epithelial cells may be a major 
target for ICS as they are activated by environmental signals and release multiple 
inflammatory proteins including cytokines, chemokines and growth factors. 
Inflammatory proteins are regulated by increased gene transcription, which is 
controlled by pro-inflammatory inflammatory transcription factors such as nuclear 
factor-ƙB and activator protein 1 (AP-1) that are activated in asthmatic cells (Barnes 
& Adcock, 1998). At cellular level corticosteroids reduce the number of inflammatory 
cells in the airways, including eosinophils, T-lymphocytes, mast cells and dendritic 
cells. These remarkable effects of corticosteroids are produced through inhibiting the 
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recruitment of inflammatory cells into the airway by suppressing the production of 
chemotactic mediators and adhesion molecules and by inhibiting the survival in the 
airways of inflammatory cells, such as eosinophils, T-lymphocytes and mast cells. 
Thus, corticosteroids have a broad spectrum of anti-inflammatory effects in asthma 
with inhibition of multiple inflammatory mediators and inflammatory and structural 
cells.  
Treatments tend to use long-acting bronchodilating agents in order to achieve 
maximum improvements; about 50% patients use these agents (Schermer et al, 
2007). Patients with frequent exacerbations-preferably those with forced expiratory 
volume in one second (FEV1) <50%-receive additional treatments by inhaling 
corticosteroids, which decrease exacerbation rate, probably by reducing the 
inflammation of lung parenchyma and bronchi (Jones et al, 2003). Corticosteroid 
therapy and long acting bronchodilating agents are currently available combined in a 
single inhaler for more severe cases, and have a clear impact on symptom relief 
(Calverley et al, 2007).  
Although combination therapy of bronchodilators with ICS is routinely used in COPD 
patients, many patients do not respond well to the treatments and still suffer greatly 
from their poorly treated condition.   This has been reported at a clinical level but 
also at a cellular level. In vitro studies of human alveolar macrophages cultured with 
varying doses of steroid showed IL-8 release was not suppressed by Dexmethasone 
(Dex) in COPD patients, however showed better responses in healthy patients 
(Culpitt et al, 2003).  Conversely, asthma although being an inflammatory lung 
condition is treated with similar drug combinations but these patients respond much 
better and have a better quality of life.  Therefore there is an ongoing and urgent 
need to develop better therapies for COPD, and to further characterize which 
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patients may respond to steroid therapy and to establish if a subgroup of patients is 
‘good responders’.   
In asthma oxidative stress is low (Montuschi et al, 1999), but in COPD oxidative 
stress is increased to a greater extent due, in part to a striking increase in the 
number of neutrophils and macrophages (Montuschi et al, 2000). This finding implies 
that histone deacetylase (HDAC) activity is likely to be much lower in COPD than 
asthma, resulting in steroid resistance. However, this is only one proposed 
mechanism and there may be others. 
1.5.2 CORTICOSTEROID RESISTANCE IN COPD 
 
COPD involves inflammation with co-ordinate expression of multiple inflammatory 
genes in the lungs. Inhaled corticosteroids show less therapeutic benefit in COPD. 
This may reflect that the inflammation in COPD is not suppressed by corticosteroids, 
with no reduction in inflammatory cells, cytokines or proteases in induced sputum 
even with oral corticosteroids. Furthermore, histological analysis of peripheral 
airways of patients with severe COPD shows an intense inflammatory response, 
despite treatment with high doses of Inhaled corticosteroids (Hogg et al, 2004). 
There is increasing evidence for an active steroid resistance mechanism in COPD, 
as corticosteroids fail to inhibit cytokines such as IL-8 and TNF-α that they normally 
suppress (Keatings et al, 1997 & Culpitt et al, 1999). In vitro studies show that 
cytokine release from alveolar macrophages is markedly resistant to the anti-
inflammatory effects of corticosteroids, compared to cells from normal smokers and 
these in turn are more resistant than alveolar macrophages from non-smokers 
(Culpitt et al, 2003). This lack of response to corticosteroids may be by an inhibitory 
effect of cigarette smoking and oxidative stress on HDAC function, thus interfering 
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with the critical anti-inflammatory action of corticosteroids (Ito et al, 2001). Indeed, 
there is a correlation between HDAC activity and the suppressive effects of 
corticosteroids on cytokine release. It is likely that oxidative and nitrative stress in 
COPD specifically impairs HDAC2 (Ito et al, 2004) resulting in steroid resistance 
(Barnes et al, 2004). Although this is seen in all stages of COPD it is most marked in 
the patients with severe disease (Ito et al, 2005). The mechanisms of glucocorticoid 
sensitivity in normal asthmatic patient is shown in (Figure 1.6) and in patients with 
COPD who have stopped smoking the steroid resistance persists and these patients 
are known to have continuing oxidative stress (Figure 1.7). 
 
                        Stimuli 
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FIGURE 1.6 MECHANISM OF STEROID SENSITIVITY IN ASTHMA 
In asthmatic alveolar macrophage (AM), nuclear factor (NF-κB) is activated following 
stimulation and switch on histone acetyltransferases (HAT), leading to histone acetylation 
and subsequently to the transcription of the genes encoding inflammatory proteins-tumour 
necrosis factor (TNF-α), interleukin (IL-8) and granulocyte macrophage colony stimulating 
factor (GM-CSF). Glucocorticoid reverses this by binding to glucocorticoid receptor and 
recruiting histone acetyltransferase (HDAC2). This reverses the histone acetylation induced 
by NF-κB and switches off the activated inflammatory genes. 
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FIGURE 1.7 MECHANISM OF CORTICOSTEROID RESISTANCES IN COPD 
In COPD and smoking asthmatic patient’s alveolar macrophage (AM), nuclear factor (NF-κB) 
is activated following stimulation but cigarette smoke generate oxidative stress (acting 
through peroxynitrite) to impair the activity of HDAC2. This amplifies the inflammatory 
response to NF-ƙB activation by histone hyper acetylation, but also reduces the anti-
inflammatory effect of corticosteroids, as HDAC2 is now unable to reverse the histone 
acetylation. (Adapted from Barnes et al., 2004). 
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1.6 STEROIDS 
 
Steroids occur naturally in human body and constitute an important class of 
hormones. Hormones are chemical compounds that are produced by specialized 
cells in the body and are released into the circulatory system. When these 
compounds reach their target cells, they elicit specific physiological responses. In 
steroid hormones it is achieved by regulating the expression of specific genes (Moss, 
1989). 
Steroid Receptors: 
 
 
FIGURE 1.8 STRUCTURE OF STEROID RECEPTOR  
Steroid receptor with its functional domain: amino terminal domain (NTD) lies towards the N-
terminal also known as activation function-1(AF-1) whereas ligand binding domain lies 
towards carboxyl terminal also known as activation function-2(AF-2). DNA binding domain 
(DBD) along with hydrogen resides in between of both AF-1 and AF-2. 
Steroid receptor consists of modulated domains with highly conserved centrally 
localized zinc-finger DNA binding (DBD) carboxyl-terminal ligand binding domain 
(LBD) and a divergent amino terminal domain (Figure 1.8). The amino terminal 
domain (NTD) is variable among receptors with exception of a region rich in 
negatively charged acidic amino acids. This region is known as either AF-1 
(Activation Function-1) or tau-1, and its function is transcriptional regulation can be 
ligand independent. The AF-1 region has been shown to interact directly with basal 
transcriptional machinery and with many other co-factors that participate in 
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transcriptional regulation, moreover, disruption of AF-1 decreases reporter gene 
expression (McEwan et al, 1993., Dahlman-Wright et al, 1995).  
1.7 GLUCOCORTICOIDS 
 
Corticosteroids are classified as natural steroids and are of three types including 
glucocorticoids, mineralocorticoids and sex hormones. Glucocorticoids regulate 
many aspects of metabolism and immune function, whereas mineralocorticoids help 
maintain blood volume and control renal excretion of electrolytes.  In humans, 
cortisol (Figure 1.9) is naturally occurring glucocorticoids from its precursor cortisone 
(Velden, 1998). The primary glucocorticoid and natural steroid hormone cortisol is 
secreted continuously by the adrenal cortex in diurnal pattern, but its release and 
effects are dynamic and increase dramatically in the setting of environmental 
stressors (Chrousos, 2000 & Hojilund et al, 2001). 
                                
FIGURE 1.9 CHEMICAL STRUCTURE OF CORTISOL:  
http://organiceyourlife.com/mind-over-body-the-cortisol-effect/ 
Cortisol synthesis in the adrenal cortex is controlled along the hypothalamic-pituitary adrenal 
axis (HPA) axis (Figure 1.9) through one of the two negative feedback loops, one direct and 
one indirect (Cowell & Buckingham, 2001, Morand & Leech, 2001).  
During anti-stress effects of glucocorticoids in diminishing the elevated levels of 
particular serum cytokines it stimulate both the hypothalamus and anterior pituitary in 
   
  
53 | P a g e  
 
many pathological contexts, e.g. trauma, infection and other forms of physiological 
stress. Cortisol secretion is supressed by classical negative feedback loops. When 
blood concentration rises above a certain threshold, cortisol inhibits CRH 
(corticotrophin-releasing hormone) secretion from the hypothalamus, which turns off 
adrenocorticotropic hormone (ACTH) secretion, leads to a turning off of cortisol 
secretion from the adrenal gland. The combination of positive and negative control 
on CRH secretion results in pulsatile secretion of cortisol (ACTH) from the anterior 
pituitary. 
 
 
FIGURE 1.10 DIAGRAM OF HYPOTHALAMIC-PITUITARY-ADRENAL AXIS (HPA) 
https://www.onnit.com/academy/cortisol-heavy-metal-and-your-health/ 
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HPA axis controls the release of glucocorticoids. The hypothalamus produces corticotrophin 
releasing hormone (CRH) which stimulates the secretion of adrenocorticotrophic hormone 
(ACTH) from pituitary gland. ACTH then stimulates the adrenal cortex to produce cortisol. 
The negative feedback system of the HPA axis keeps glucocorticoid concentration within a 
normal range. 
 
1.7.1 GLUCOCORTICID RECEPTORS 
 
Glucocorticoids are used as potent immunosuppressive and anti-inflammatory 
agents in the management of many inflammatory allergic, autoimmune & 
lymphoproliferative diseases. The actions of glucocorticoids are mediated by multiple 
isoforms of an intracellular receptor protein, the glucocorticoid receptor, which 
belongs to the steroid /sterol nuclear receptor superfamily, functioning as a hormone 
activated transcription factor that regulates the expression of a large number of 
glucocorticoid responsive genes (Kino et al, 2003).  
The hGR gene consists of 9 exons and is located on chromosome 5 (Nicolaides et 
al, 2010). There are 9 exons in the hGR gene: exon 1 (  ̴ 116-981 bps) is a leader 
sequence, exon 2 (1197 bps) contains the coding sequence for AF-1 at the amino-
terminal, exon 3 (167 bps) and exon 4 (117 bps) code for the first and second zinc-
finger motif in the DBD respectively, exon 5 (280 bps), exon 6 (145 bps), exon 7 (131 
bps), exon 8 (158 bps) codes for AF-2 and a large portion of the DBD, and exon 9 
(4,108 bps) contains coding sequences for the two alternative carboxyl terminal of 
the LBD, α and β, and their respective 3' regions (Lu & Cidlowski, 2004) (Figure 1.8 
and 1.11). In human cells total 777 amino acids are found which results from either 
posttranscriptional splicing of RNA or differences in start points. The main two types 
are GR α and GR β (Cidlowski, 2006). 
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  FIGURE 1.11 HUMAN GLUCOCORTICOID RECEPTOR GENE 
The diagram represents genomic location and structure of human glucocorticoid 
receptor gene (hGR). Alternative splicing of primary transcript give rise to the two 
mRNA and protein isoforms: GR- α and GR- β and post translational modifications in 
the form of phosphorylation (P), ubiquination (Ub) and Sumoylation (Sumo). DBD 
denotes DNA binding domain, LBD-Ligand binding domain and hGR human GR 
(Adapted from Rhen and Cidlowski, 2005). 
 
 
   
  
56 | P a g e  
 
GR α:  
Human glucocorticoid receptor (hGR) α resides primarily in the cytoplasm of cells 
with several heat shock proteins (hsps) and represents the classic glucocorticoid 
receptor that functions as a ligand-dependent transcription factor. Glucocorticoid α 
isoforms undergo a confrontational change when binding to hormone which results in 
dissociation of hsps, activation of their nuclear localization signals (NLS) and 
translocation into the nucleus (Kino & Chrousos, 2004 & Kino et al, 2003). Ligand 
activated GR α isoforms binds on to glucocorticoid responsive elements (GREs) in 
the regulatory regions of so-called co-activators and chromatin remodelling factors 
and influence transcription (Kino & Chrousos, 2004). Alternatively, GR α isoforms 
interact with other transcription factors, such as nuclear factor ƙ β and the activator 
protein 1 (AP1) to influence the transcription of genes responsive to these factors. 
GR β: 
 
GR β isoforms are identical to GR α but with a different c-terminal region, having 15 
non-homologous amino acids at their c-terminal end (Hollenberg et al, 1985). Thus, 
GR β isoforms share the same N-terminal (NTD) and DNA-binding (DBD) domains 
with GR α, but possess unique "ligand binding" domain (LBD).  GR β are located 
mainly in nucleus and generally fail to activate the transcription of glucocorticoid 
responsive gene (Castro et al, 1996).  GR β function as dominant negative isoforms 
of GR α-induced transactivation of GRE containing glucocorticoid- responsive 
promoters and functions as natural inhibitor of glucocorticoid actions (Lu et al, 2004, 
Castro et al, 1996 & Bamberger et al, 1995). The ability of GR β to antagonize and 
moderate GR α effects suggests that GR β may play an important role 
in the regulation of target cell insensitivity to glucocorticoids. The expression of GR β 
is induced by cytokines and an increase of the GR β/GR α ratio has been reported in 
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patients with bronchial asthma, rheumatoid arthritis and 
chronic lymphocytic leukaemia (Vottero & Chrousos, 1999 & Lu et al, 2004). 
In asthma, the ratio of both the isoforms vary as the glucocorticoid receptor GR α is 
linked with steroid sensitivity whereas the association between glucocorticoid 
insensitivity is due to increased glucocorticoid receptor GR ß expression (Pujols et 
al, 2007). However, reports suggest the ratio of GR α and β does not vary in COPD 
patients (Korn et al, 1998). Therefore, does not provide a suitable explanation. 
Glucocorticoids induced gene transcription: 
Glucocorticoids exert their effects by binding to a cytoplasmic GR, that has several 
domains, including ligand binding domain, a DNA binding domain and 2 domains 
that are involved in transactivation of genes once binding to DNA has occurred via 
association with other proteins (Karin, 1998). The GR is a ligand induced 
transcription factor, which regulates gene expression through binding to a specific 
response element on the DNA in an indirect manner by interacting with other 
transcription factors such as nuclear factor-KB (NF-kB), activator protein (AP-1), 
Signal Transducer and Activator of Transcription (STAT) and Nuclear Factor of 
Activated T cells (NFAT) (Tait et al, 2008). GR is expressed in almost all cell types, 
including bronchial epithelial cells, and is retained inactive in the cytoplasm by a 
multi-protein chaperon complex heat shock protein (hsps-90) (Howard & Distelhorst 
1988, Adcock & lane, 2003 & Pujols et al, 2009). Upon hormone binding, GR 
conformation is modified by dissociation of hsps-90 complex and translocate to 
nucleus. In nucleus GR binds as homodimer to specific DNA motifs termed as 
Glucocorticoid Responsive Elements (GREs) and activates transcription of GRE 
containing genes (Dahlman-Wright et al, 1990 & Luisi et al, 1991). It can also 
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repress gene transcription via protein-protein interaction independent of DNA 
recognition (Yamamoto, 1995). Gene activation and transcription is facilitated when 
the helical structure of DNA is unwound, and so enabling rapid onset of transcription 
by RNA transcriptase activity.  For this to happen the histone structures that the DNA 
is wound around need to be acetylated to enable an ‘open’ conformation.  
 
 
FIGURE 1.12 GLUCOCORTICOID INDUCED GENE TRANSCRIPTION 
Glucocorticoid activation of anti-inflammatory gene expression. After ligand binding, 
activated glucocorticoid receptors (GRs) translocate to the nucleus where they bind to 
glucocorticoid responsive elements (GREs) in the promoter region of glucocorticoid 
responsive genes and also directly or indirectly to transcriptional coactivator molecules such 
as cyclic AMP response element binding protein (CBP). Coactivator molecule has intrinsic 
histone acetyl transferase activity (HAT) and cause acetylation of anti-inflammatory genes. 
SLPI-Secretory leucoprotease inhibition. 
Conversely genes can be ‘switched off’ or deactivated by de-acetylating the histones 
so they can revert to the ‘closed’ conformation. (Figure 1.12). Glucocorticoid 
operates by binding to the cytosolic steroid receptor (GR) that enables the hormone 
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receptor complex to translocate to the cellular nucleus.  In the nucleus the GR-
hormone complex binds to glucocorticoid response elements (GRE) in the promoter 
region of steroid-sensitive genes. This leads to recruitment and activation of 
transcriptional coactivator molecules such as CBP, steroid receptor co-activator-1 
(SRC-1), or other cofactors that have intrinsic HAT activity. This, in turn, results in 
acetylation of specific lysine residues on core histones proteins. Chromatin 
modification leads to local unwinding of the DNA structure, allowing recruitment of 
large protein complexes including RNA polymerase II. HATs cause acetylation of 
lysines on histone H4, which leads to activation of genes encoding anti-inflammatory 
proteins, such as secretory leukoprotease inhibitor (SLPI). 
1.7.2 GLUCOCORTICOID RECEPTORS PHOSPHORYLATION 
 
Glucocorticoid receptors are transcriptional regulatory phosphoproteins (Dalmann et 
al, 1988 & Bodwell et al, 1991). Post translational modifications of GR regulate target 
gene specificity and involve several cell signalling cascades (Davies et al, 2008). 
Phosphorylation, acetylation and SUMOylation of the GR are few examples of 
important modification of the GR after its translation. The GR undergoes several 
modifications following the mRNA translation into a polymer of amino acids. Such 
modifications not only play an essential role in determining the final structure of the 
GR, but also participate in establishing its function as a steroid dependent gene 
expression regulator (Holmstrom et al, 2008 & Brandl et al, 2009). Glucocorticoid 
receptors phosphorylation status can affect a range of GR functions, including DNA 
binding and transactivation potential, hsp90 interactions, subcellular localization and 
nuclear cytoplasmic shuttling (Adcock & Ito, 2005).  This suggests that GR 
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phosphorylation may be one of the molecular mechanisms of corticosteroid 
resistance.  
1.7.3 THE ROLE OF SERINE 211 (S211) 
 
The most common sites for phosphorylation are serine. In human GR seven serine 
residues can be phosphorylation targets- S113, S134, S141, S203, S211, S226 and 
S404 (Oakley & Cidlowski, 2013). GR is usually phosphorylated at conserved 
residues suggesting a conserved function of phosphorylation. There are several 
kinases that phosphorylate the hGR α in vivo and in vitro. These includes 1) the 
yeast cyclin dependent kinase p34CDC28 (Ismailli, 2004 & Wang et al, 2002), 2) the 
p38 mitogen-activated protein kinase (MAPK) (Miller et al, 2005), 3) the CNS-specific 
cyclin-dependent kinase (CDK5) (Kino et al, 2007), 4) the glycogen synthase kinase 
3 β (GSK-3 β) (Rogtsky et al, 1998 & Gulliner-Beckley et al, 2008), 5) the c-Jun N-
terminal kinase (JNK) (Rogatsky et al, 1998 & Itoh et al, 2006). The 3 
phosphorylation sites- Serine 203 (S203), Serine 211 (S211) and Serine 226 (S226) 
lies on N-terminal of human gene. The N-terminal transcriptional domain site S211 
and S203 is targeted by CDK and p38 kinases (Bodwell et al, 1991& Davies et al, 
2008) whereas S226 is phosphorylated by JNK pathway (Kristic et al, 1997). GR 
becomes phosphorylated on activation in various amino acid locations at its N 
terminus (S203, S211 and S226) which affects their ability to interact with other 
proteins. Mutation in CDK genes in yeast reduce GR-dependent transcriptional 
activation, suggesting that phosphorylation of S203 and S211 is required for full GR 
transcriptional enhancement (Wang and Garabedian, 2003). Also, S211 acts as a 
substrate for p38 MAPK (Miller et al, 2005). In contrast, phosphorylation of S226 by 
JNK inhibits GR transcriptional activation (Rogatsky et al, 2003).  This type of 
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phosphorylation results in inhibition of GR activity, possibly because of increase in 
GR nuclear export (Itoh et al, 2002). Studies have shown GR transcriptional 
activation is greatest when the relative phosphorylation of S211 exceeds that of 
S226 (Chen et al, 2008).  Figure 1.13 show phosphorylated and non-phosphorylated 
sites for S211. The non-phosphorylation confirmation exhibits random conformation 
of unmodified proteins whereas; the phosphorylated S211 induced a marked trend 
towards a more structured conformation with the peptide adapting a helical structure 
on both sides of the phosphorylation site. 
 
FIGURE 1.13 GLUCOCORTICOID PHOSPHORYLATION OF S211 
Representative low-energy confrontations of: (A) Non-phosphorylated and (B) 
Phosphorylated (P-S211) peptide spanning the S211 site. Peptide is coloured blue 
(N-term) to red (C-term) and S211 is depicted. (Adapted from Mol. Endocrinology 
Chen et al, 2008). 
 
1.7.4 THE ROLE OF CO-FACTOR TETRATRICOPEPTIDE 5 (TTC5) 
 
Chronic obstructive pulmonary disease is an inflammatory disorder involving 
abnormalities in both innate and adaptive immune response. The process of 
inflammation, metabolism and immune response are regulated by glucocorticoids 
which are activated by glucocorticoid receptors (GR) (Wang et al, 2004). These 
activities are regulated at multiple levels including protein stability, post translational 
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modifications and cofactors interactions. During the transcriptional activity the 
hormone binds with the GR; translocate to the nucleus and binds to glucocorticoid 
response elements in the regulatory regions of its target genes. TTC5 is a stress 
responsive protein, also known as stress-responsive activator of p-300 (STRAP) and 
is present at GR regulated promoter region and can regulate the transcriptional 
activity of GR, acting as a co-activator or co-repressor in a gene specific manner. 
According to Davies et al (2011) findings in responsive stress manner, TTC5 
interacts and stabilizes GR protein and regulates transcriptional activities. The 
regulation of GR by TTC5 is likely to contribute to the physiological role of the 
glucocorticoids.  
TTC5 is composed of six protein-protein interactions tetricopeptide repeat (TPR) 
motifs distributed throughout its sequence (Demonocas et al, 2001) and also 
contains one LXXLL (where L is leucine and X is any amino acid) nuclear receptor 
(NR) interaction motif between TPR 4 and TPR 5. However, mutation of LXXLL motif 
sequence and TPR motifs 2, 3 and specifically 6 not only reproduces alterations in 
interaction with receptors but also reduces the binding activity with GR (Davies et al, 
2011) (Figure 1.14). 
GR transcriptional effects are also modulated by co-regulators- TTC5 
tetratricopeptide 5 which is thought to stabilized GR and alter its responses to 
cellular stress in a both positive and negative fashion.   There is very little information 
about the expression of TTC5 in lung COPD tissue in comparison to healthy control 
patients; or how its regulation may be modulated by cigarette smoking (Davies et al, 
2011).  
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FIGURE 1.14 STRUCTURE OF TETRATRICOPEPTIDE 5 OR STRAP 
Ribbon structure of STRAP (TTC5). It is elongated monomeric structure composed 
of two domains-a 250-residue N-terminal all α-helical domain comprising of 6 tandem 
TPR motifs and C terminal all ß-sheet oligonucleotide/oligosaccharide binding (OB) 
fold. The domains are connected by a linker region containing a TPR-capping helix 
(H7) and a small perpendicular Helix (H8). The yellow spheres denote the 
phosphorylation sites.  
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1.8 AIMS AND OBJECTIVES 
 
This thesis has the following research objectives: 
1.8.1 To build on previous research from the fibrosis inflammation repair (FIR) 
group at Salford University to characterise EMT linked biomarkers in COPD and 
healthy control patients 
 S100A4 was most strongly linked with smoking history and COPD 
development in previous studies, compared to other EMT related biomarkers.  
Therefore, this study aimed to further expand the patient numbers used for 
histochemical analysis of S100A4 expression in human lung tissue. 
 
1.8.2 To build on nationally published data and Salford FIR group information on 
the properties of GR expression in COPD lung tissue.   
 To charactise the degree of serine 211 (S211) phosphorylation expressions 
between the two subject groups, the hypothesis being there may be 
differential expression between COPD patients and control subjects. 
 To characterise the degree of expression of GR-cofactor tetratricopeptide 5 
(TTC5) in COPD patients compared to healthy controls; to address the 
hypothesis that differential expression between patients and control subjects 
may exist. 
 
Collectively, this information will further the field of COPD research by offering 
insight into the mechanisms of EMT process in COPD, and the potential 
mechanisms of steroid resistance.  
 
 
 
 
 
   
  
65 | P a g e  
 
2. METHODS 
2.1 SAMPLE SUBJECTS 
 
Primary human lung samples were collected from patients suffering from chronic 
obstructive pulmonary disease recruited from Wythenshawe hospital. These patients 
had in most cases undergone resection surgery for tumour excision as part of their 
NHS treatment. The subject demographics were also obtained including their age, 
lung function, sex, medication and smoking status, although this data was blinded 
until statistical analysis was required preventing any influenced or biased data 
collection. All subjects gave written informed consent. The study was approved by 
the local research ethics committee (South Manchester). 
Table 2.1 Patient Demographics: 
VARIABLES CONTROL SUBJECTS (N=27) COPD SUBJECTS (N=19) 
NON-
SMOKER 
CURRENT 
SMOKER 
EX-
SMOKER 
COPD 
CURRENT 
SMOKER 
COPD EX-
SMOKER 
SUBJECTS 5 8 13 8 11 
SEX M/F 2/3 3/6 8/5 4/4 10/1 
AGE 70±12.56 62.12 
±10.73 
72.23 
±10.63 
65.75 ±8.95 69.72 
±5.76 
PYH N/A 42.75 
±25.49 
38.69 
±25.06 
68.2 
±64.82 
59.68 
±33.01 
FEV% 
PREDICTED 
97.4 
±5.17 
75.37 
±24.42 
85.53 
±17.58 
65.12 
±19.03 
65.42 
±19.54 
FEV1/FVC 
RATIO 
60.92 
±35.56 
77.36 
±10.78 
62.49 
±8.55 
48.31 
±1.54 
58.93 
±10.23 
*Data are presented as mean SD. N/A - not applicable. PYH-Pack Year History=1 year smoking 20 
cigarette per day. FEV1-Forced Expiratory Volume in 1 second. FVC-Forced Vital Capacity 
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2.1.2 PROCESSING OF LUNG BIOPSIES 
 
Fixation was done as the first step to preserve the tissue substrate and render 
protein structure and other tissue components insoluble in all reagents exposed later 
in either processing or staining process. By fixation, autolysis and putrefaction can 
be halted and tissue substrates can be preserved. Formalin is mostly used as 
fixative agent because of its high penetration rate and preserve tissue for longer 
period of time.  
After fixation, tissues were insufficiently firm and cohesive to allow thin section to be 
cut. This is why processing must be carried out. However, before the processing, 
about 3-5mm thick slices of lung tissue were obtained and put into tissue dek 
cassettes. The cassettes were then labelled for their laboratory accession number 
with lead pencils. Dehydration was then carried out to remove all water in tissue 
substrate so that water droplets will not trap and affect the specimen from being 
processed. Ethanol was used in dehydration process as it has least side-effects on 
tissue substrates compared to other dehydration agents. Water molecules were 
removed in ascending grades of alcohols to absolute alcohol.  
Wax is insoluble in ethanol. Clearing agent that was miscible in both ethanol and 
wax are required. As xylene has least effect on tissue substrate, it was used in the 
experiment. However, xylene can harden the tissue, thus the immersion time cannot 
be prolonged.  
After the clearing process, tissues were then infiltrated with wax. Additives such as 
bee’s wax or synthetic resin were added to increase the hardness and stickiness of 
wax in order to give better cutting properties on tissue by altering the size of wax 
crystals. Temperature of the wax was kept 2° to 3°C above the melting point of wax 
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(~60°C) so that the wax will remain as liquid form throughout tissue infiltration 
process. However, it is important to make sure that the wax did not overheated as it 
would destroy plastic polymers and cause the cutting process to become more 
difficult. 
In overall view, the tissue substrates were immersed in the reagents as shown: 
1) 50 % Ethanol for 1 hour 
2) 90% Ethanol for 1 hour 
3) Absolute Alcohol for 1 hour (x2) 
4) Xylene for 1 hour(x2) 
5) Paraffin wax for 90 minutes (x2) 
The whole process of dehydration, clearing and infiltration of wax was done on an 
automatic tissue processor (Leica, TP1020).  
2.1.2.1 EMBEDDING 
 
Before the cutting, processed tissue needs to be embedded in wax as a 'block' form 
to enable the section to be cut. Tissue cassettes molds method was applied as it did 
not require further trimming of wax around the tissue. For embedding process little 
wax was poured into the tissue molds and allowed to form at the bottom layer of the 
molds. Tissues were then picked with warm forceps and put onto the centre of the 
molds. Plastic tissue cassettes were placed over the mold. More wax was added into 
the molds if necessary. The molds were then moved to cold plate for rapid cooling 
and give fine crystalline structure to wax for better cutting properties. 
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2.1.2.2 MICROTOMY 
 
As the sample moulds get solid the specimens were clamped into position on the 
microtome, (Leica, RM2125) by rotating the hand wheel clamp until the specimen 
clamp fit in the uppermost position and the handle locked in an upright position. The 
sample block could then be locked into the specimen clamp. By gentle turning the 
handle, thickest portion of the block started to trim, knife or blade was inserted in 
proper position so that the section obtained were trimmed at desired level of 5 µm 
thickness. The desired ribbon of tissue samples were mounted on to microscopic 
slides (Menzel-Glaser, Thermo Scientific, Braunschweig) for visualisation. Each 
sample was mounted gently transferring the section into the water bath set to 10°C 
below paraffin melting point of 50°C and then onto the microscopic slides, holding 
the slide half away in the water and gentle lifting out whilst the section began to stick, 
effectively pulling the section onto the slide. Tissues were air dried. Ensuring the 
handle wheel lock was in the upright position and the blade edge of the knife guard 
covered, the specimen could be removed. Using the coarse feed wheel a new 
specimen could then be loaded and new section ribbons were produced.   
2.1.3 IMMUNOHISTOCHEMISTRY TECHNIQUE (IHC) on FFPE TISSUES 
 
IHC is a powerful microscopy based technique for visualizing cellular components. 
The IHC technique was invented in 1940s (Coons, Creech & Jones, 1941) and is 
routinely used as an important tool in health care and pathology for e.g., diagnostic 
purposes to stratify patients for optimized treatment regimes. Figure 2.1 shows the 
process of binding primary and secondary antibodies with appropriate proteins. 
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FIGURE 2.1 SCHEMATIC DIAGRAM OF IMMUNOHISTOCHEMISTRY. 
 
2.1.3.1 OPTIMISATION 
 
To confirm the antibody specificity and to achieve the best dilution, antibody 
optimisation was carried out. For this, different sets of dilutions were tested against 
given antibodies. The table 2.1 shows the optimal dilutions for antibodies required. 
Table 2.2 OPTIMAL DILUTION 
Primary 
Antibody 
Monoclonal Source Cat no. Dilution Pre-
treatment 
S100A4 Rabbit Dako A5114 1:2500 N/A 
TTC5 Rabbit Dako T3503-15 1:500 N/A 
S211 Rabbit Dako 4161100  
 
1:1000 EDTA 
buffer 
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DAY 1: 
Dewaxing of the samples through xylene for two sessions of five minutes each was 
performed, followed by rehydration through alcohol dilutions of 100% for 5 minutes, 
90 % for three minutes, 75 % for two minutes and 50 % for one minute. The samples 
were then placed and run under water for five minutes, followed by pre-treatment. 
Pre-treatment involves the slides being placed in pre-treatment (PT) module and run 
for about 45 minutes per cycle. According to the antibody optimisation, S211 primary 
antibody needs a pre-treatment with EDTA buffer. 1mM EDTA was prepared by 
dissolving 0.37g of EDTA in 1000ml distilled water with pH 8.  
Samples were then placed under running water for five minutes and then carefully 
each slide was dried with tissue paper, care was taken not to wipe away the sample, 
and for each slide the sample sections were drawn with a PAP wax pen, (Sigma, 
UK). Each sample was then blocked in 100µl of vector normal goat serum, (Elite Px, 
UK), 75µl in 5ml of TBS buffer, (Salford University Stores, UK), for thirty minutes at 
room temperature, followed by incubation in 100µl of primary antibodies S100A4 
(1:2500) anti human rabbit antibody, S211 (1:1000) and TTC5 (1:500) for each 
COPD patients and control subjects (Elite, Px, UK).  
The primary antibodies were prepared by using PBS; the samples were then 
incubated overnight at a room temperature in a humid box to prevent tissue 
dehydration.   
DAY 2: 
After overnight incubation in primary antibodies each sample was then washed in 
TBStween buffer for three sessions lasting three minutes each. TBS tween was 
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prepared from 500ml of 1xTBS (10x stock TBS, (Fisher, UK) diluted to 1:10 with 
distilled water) dissolved in 500µl of Tween-20. The samples were then placed in 
vector biotinylated secondary antibody, (Elite, Px, UK) for thirty minutes at room 
temperature. Vector biotinylated secondary antibody was prepared by adding 15µl of 
normal blocking serum to 1 ml TBS in a mixing bottle, then 5µl of biotinylated 
antibody stock was added to the mixture. Samples were then washed again in 
TBStween for three sessions lasting for three minutes each. 
Each sample slide was then blocked of endogenous peroxidase by incubating in 40µl 
of 3% Hydrogen peroxide, (Fisher, UK) in methanol, (Salford University Stores, UK) 
for thirty minutes at room temperature. During this incubation period the avidin biotin 
complex (ABC), (Elite, Px, UK) was prepared as it was required to be prepared thirty 
minutes earlier before use. Preparation of ABC involved two drops of reagent A 
being added to 5ml of TBS, then two drops of reagent B added and mixed 
immediately standing for thirty minutes. After thirty minutes incubation at room 
temperature each sample was then washed in TBS tween for three sessions lasting 
three minutes each.  
Following washing, each sample was then incubated in DAB substrate, (Vector, UK) 
until the sample turned visibly brown; this took approximately thirty minutes to an 
hour. A microscope was focused on each sample to stop the reaction following DAB 
stain has been reached. After this the samples were held under running water for a 
further five minutes. Counter stain was initially performed with Haematoxylin for 25 
seconds and then samples were run under water. Dehydration back through alcohols 
occurred at dilutions of 50 % alcohol for one minute, 75 % for two minutes, 90 % for 
three minutes and 100 % for five minutes, each slide could be mounted with a cover 
slip containing DPX and visualized under the microscope. 
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2.1.3.2 MICROSCOPIC IMAGING 
 
Digital microscopic images were obtained using a Leica microscope equipped with 
an imaging digital camera and Leica software. All images were stored as jpg and 
were cropped, where applicable, using Adobe Photoshop. 
2.1.3.3 IMAGE ANALYSIS 
 
Wayne S Rasband created a program named as Image J at NIH in 1987 (cited in 
Schneider et al, 2012). It is a free programme that can be downloaded from the 
website: http://rsbweb.nih.gov/ij/download.html  
It is an open source image processing program for multidimensional image data with 
a focus on scientific imaging. It is incorporated with number of macros and plugins 
like Image processing, co-localization, deconvolution, registration, segmentation, 
tracking, visualization, cell counter and much more. The following Figure. 2.2 show 
the different stages of colour deconvolution.  
 
Figure 2.2 Images depicts the stages of colour deconvolution by Image J software. (Fig 2.2 
A) shows normal Image with subtracted background, (Fig 2.2 B, C, D) shows 3 different 
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stained images by colour deconvolution, (Fig 2.2 E) depicts the threshold value and (Fig 2.2 
F) shows the percentage area stained. 
In Figure 2.2 for the first stage, the standard historical stain combination of 
haematoxylin & eosin (H&E) and 3, 3-diaminobenzidine (DAB) substrate with 
haematoxylin has been segmented by plugin deconvolution. In next stage, Image 
has been split into three components according to the colour stain used. Figure 2.2 B 
colour is brown because of DAB substrate, figure 2.2 C is haematoxylin, it is purple 
and figure 2.2 D is residue. Following deconvolution, thresholding was performed on 
figure 2.2 B to select the area of interest for measuring area stained and thus figure 
2.2 E was obtained and in final stage the black area in figure 2.2 D shows the 
selected percentage area of the given stained image.  
2.1.4 STATISTICAL ANALYSIS OF IHC IMAGES  
 
Data were analysed in Graph Pad Prism 5 and statistics performed in Graph Pad 
Instat 3 (Graph Pad software, San Diego, CA, USA; http://www.graphpad.com). 
Immunohistochemistry data were normally distributed.  
Non-parametric repeated One-way ANOVA (Kruskal-Wallis) test was performed to 
compare biomarker expression within the groups and when p<0.05 subsequent 
unpaired tests t tests were performed to compared % area stained between groups. 
Unpaired t tests were used to analyse expression of biomarkers in healthy subjects 
(control) vs. COPD subjects. 
Linear regression was performed to understand lung function (disease severity) and 
smoking history (pack year history) with biomarker expression.  
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3. RESULTS 
 
3.1 ANTIBODY OPTIMISATION 
 
In this experiment, fixation was the first step carried out for processing of lung 
biopsies to preserve the tissue. This fixation process during paraffinisation may 
create cross-linking of proteins. This may result in masking of the epitopes, resulting 
in weak or false negative staining. So, the process of antibody optimisation was 
carried out for determination of a particular epitope to expose at optimal pre-
treatment for required lung tissue and to achieve the dilution for the antibodies 
relevant to pre-treatment condition. 
The antibody for Epithelial Mesenchymal Transition marker was S100A4. 
The selected antibodies for Glucocorticoid Receptors expressing co-factor antibody 
was TTC5 and Phosphorylated Glucocorticoid receptor antibody was S211. 
According to the protocol provided by the antibody manufacturer, antibody 
concentration was tested on the COPD lung patient samples. Each antibody 
(S100A4, TTC5 and S211) was optimised on by doing serial dilution and with 
different buffers on lung patient 773. The conclusion of the antibody optimisation 
protocol (Figure 3.1) was that glucocorticoid antibody that detects glucocorticoid 
receptor phosphorylated at serine S211 required pre-treatment with EDTA buffer at 
pH 8 and the optimal antibody concentrations was 1:1000, for S100A4 and TTC5 
was 1:2500,1:500 respectively (Figure 3.2). 
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FIGURE 3.1 IHC OPTIMISATION OF S211 
Lung sample 773 images depicts the staining that was achieved during S211 
optimisation and used to determine the optimal dilution and pre-treatment condition 
(Red mark), for the samples used in the study. X100 magnifications. 
 
 
 
 
 
 
 
 
 
FIGURE 3.2 ANTIBODY OPTIMISATION OF S100A4 AND TTC5   
Lung sample images show the optimal concentration for S100A4 and TTC5 
antibodies (no pre-treatment). X100 magnifications. 
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The Figure 3.2 shows example of images of the antibody optimisation for S100A4 
and TTC5 shown across the different ranges of dilutions. Both antibodies were 
treated with IHC pre-treatment buffers and different dilutions. During the 
experimental conditions, the result obtained suggests there was no need of pre-
treatment as the clearest positive staining was observed without the pre-treatment.  
For Epithelial Mesenchymal Transition marker S100A4 (1:2500 black mark) dilution 
was chosen, as the lower dilution shows heavy areas of staining and higher dilution 
shows no positive staining compared to the chosen one.  
For TTC5, the Glucocorticoid receptor variant, lower dilutions barely show any 
stained areas compared to the chosen one (1:500 black mark) dilution which depicts 
the distinguishable structure of the lungs with positive staining.   
3.2 QUANTIFICATION OF IMAGES 
 
3.2.1 HISTOPATHOLOGICAL FINDINGS 
 
The following (Figure 3.3) depicts the example of the control subjects in comparison 
with COPD subjects with antibody staining of the lung tissue. The control subjects 
show the intact structure and COPD shows the poor prognosis in compare to 
staining between all groups. 
Figure 3.3 demonstrates the comparison between the control subject and COPD 
subject with appropriate antibody staining. (Figure 3.3 A) shows the bronchial 
epithelium (black arrows) with small basal cells sitting directly on basement 
membrane and upper layer covered with different epithelium cells. (Figure 3.3 B) 
shows the lumen of bronchiole (black arrow) within the lung parenchyma and pleura 
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with vessel (black arrow) within, these are little oedematous. (Figure 3.3 C) depicts 
the alveolar space is clear compare to the COPD subjects.  
For COPD subjects (Figure 3.3 E) shows the accumulation of fine particles of carbon 
in the lung (Cigarette tar deposits). (Figure 3.3 F) demonstrates the thin alveolar wall 
surrounding the lung parenchyma, in (Figure 3.3 G) black arrows shows 
inflammation due to presence of lymphocytes, and black arrow shows disrupted 
alveoli.  
Figure 3.3 D and H images depicts the slide stained without any primary antibody. 
(Figure 3.3 D) shows the intact structure with normal epithelial cells (black arrows) 
and (Figure 3.3 H) shows the disrupted and broken lung tissue (black arrows). There 
is a clear difference between the patient groups for epithelial marker S100A4 
staining, glucocorticoid receptor markers TTC5 and S211 between control subjects 
and COPD subjects.  
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FIGURE 3.3 IHC OF CONTROL SUBJECTS VS COPD SUBJECTS 
Examples of Epithelial Biomarker (S100A4), Glucocorticoid receptor (TTC5)              and 
Phosphorylated glucocorticoid receptor (S211) were investigated in situ using 
immunohistochemistry in (A-D) healthy non-smokers vs. (E-F) COPD current smokers. A) 
Bronchiole, B) Lumen of Bronchiole, C) Alveolar spaces are clear, D) lymphocytes, E) Tar 
deposits, F) Thin alveolar wall, G+H) Disrupted alveoli. X100 magnifications. 
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3.2.2 PATHOLOGICAL FINDINGS 
 
To analyse the immunohistochemical investigation of Epithelial Marker-S100A4 and 
glucocorticoid receptors connected markers-TTC5 and S211, a series of staining 
was performed between the patient demographics groups (Initially blinded) of 
healthy non-smoker, current smokers, Ex-smokers, COPD- current smokers and 
COPD Ex-smokers in comparison with the negative control. The microscopic images 
with appropriate antibody staining have been described.   
The human lung tissue specimens from healthy non-smokers were found to be 
having an intact parenchymal structure. Small airways were visible with considerable 
amount of lymphocytes present. Bronchioles were covered with smooth muscle cells 
and connective tissue. Alveolar walls were intact. The sections in (Figure 3.4) show 
positive staining with S100A4.  The bronchioles are clearly visible in (Figure 3.4 A) 
with infiltration of some lymphocytes and some positive cells stained for S100A4 in 
(Figure 3.4 B). Glucocorticoid receptor expressing components TTC5 and S211 both 
show some weak amount of staining compared to S100A4 with distinguishable 
features of the tissue. (Figure 3.4 C+D) shows infiltration of lymphocytes and positive 
brown cells for TTC5. Alveolar sacs were found in (Figure 3.4 E) and infiltration of 
positive cells in lumen of bronchiole which is beneath the epithelium (Figure 3.4 F). 
The negative control shows leucocytes (Figure 3.4 G+H). 
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FIGURE 3.4 IHC OF HEALTHY NON SMOKER 
Human lung tissue specimen from healthy non-smoker stained for S100A4, TTC5 and S211 
compared to negative control. Figure 3.4 A shows bronchioles (black arrows) & figure 3.4 B 
black arrow shows positive cells for S100A4. Figure 3.4 C+D black arrows indicate infiltration 
of lymphocytes and positive cells for TTC5. Figure 3.4 E detachment of alveolar ducts (black 
arrow) and figure 3.4 F black arrow show lymphocytes. In negative control figure 3.4 G+H 
black arrow points for leucocytes. X100 magnifications (column A) and X400 magnifications 
(column B).  
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The pathological findings of current-smokers are illustrated in Figure 3.5 for 
epithelial marker S100A4, Glucocorticoid receptors expressing variants TTC5 and 
S211 in comparison with negative control. A partially condensed structure was 
notified in the specimens obtained for current smokers. A moderate amount of tar 
deposits was observed. Thickening and remodelling was observed in (Figure 3.5 
A+B). The reaction with TTC5 shows a positive reaction indicating the presence of 
GC receptors. Presence of brownish cells within the respiratory bronchioles is shown 
(Figure 3.5 C+D).  Slightly weak reaction was observed for S211 antibody having 
terminal bronchiole continuing with the respiratory bronchiole, which extends into the 
alveolar ducts and ultimately the alveoli (Figure 3.5 E+F). In (Figure 3.5 G+H), the 
presence of brownish pigmented indicates the macrophages within the respiratory 
bronchioles and alveolar ducts may be associated with Peri-bronchiolar chronic 
infiltrate of lymphocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
  
82 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.5 IHC OF CURRENT SMOKER  
Human lung tissue specimen from current smoker stained for S100A4, TTC5 and 
S211compared to negative control. Figure 3.5 A+B indicates thickening of tissue (black 
arrows). Figure 3.5 C+D black arrows shows positive cells for TTC5. Figure 3.5 E shows 
alveolar ducts/alveoli (black arrows) and in figure 3.5 G+H black arrow points towards 
macrophages. X100 magnifications (column A) and X400 magnifications (column B). 
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The pathological findings of Ex-smokers are illustrated in (Figure 3.6) for epithelial 
marker S100A4, Glucocorticoid receptors related markers TTC5 and S211 in 
comparison with negative control. The presence of tar deposits was obvious 
because of the cigarette smoke in the given patient tissue sample.  The architecture 
of lung parenchyma is in intact form. Lower number of macrophages and 
lymphocytes was detected. The epithelial marker S100A4 shows reduced 
expressions with considerable number of lymphocytes (Figure 3.6 A+ B). Ex-
smokers show high reactivity with TTC5 expressed in epithelial cells, (Black arrows 
in Figure 3.6 C+ D). There was an inadequate expression of S211 in tissue sample 
of Ex-Smokers (Figure 3.6 E+ F). The negative control also depicts the thickness of 
the epithelial cell lines and lymphocytes in (Figure 3.6 G+ H). 
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FIGURE 3.6 IHC OF EX-SMOKER 
Human lung tissue specimen from ex-smoker stained for S100A4, TTC5 and S211 
compared to negative control. Black arrows in figure 3.6 A+B shows presence of 
lymphocytes. In figure 3.6 C+D black arrows indicates the thickening of epithelial linings. 
Figure 3.6 E+F shows minimal positive cells for S211 (black arrows) and figure 3.6 G+H 
depicts the thick epithelial lining. X100 magnifications (column A) and X400 magnification 
(column B). 
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Figure 3.7 + Figure 3.8 shows the immunohistochemical staining for epithelial marker 
S100A4, Glucocorticoid receptor markers TTC5 and S211 in COPD Current 
smokers (CCS) and COPD Ex-smokers (CEX) respectively.  In CCS, partially 
condensed structures and airway remodelling were observed in lung tissue samples. 
S100A4-epithelial marker was expressed positively in (Figure 3.7 B). Deposition of 
tar and capillaries are present in (Figure 3.7 A). Glucocorticoid receptor 
markersTTC5 and S211were also expressed positively in the lung tissue of CCS. 
Infiltration of lymphocytes and macrophages are present in (Figure 3.7 C). 
Pigmented macrophages are also seen in (Figure 3.7 D). Alveolar detachment and 
spindle shaped cells in the epithelial cell lines may indicate the presence of fibrosis 
in the patients with CCS (Figure 3.7 E+ F). Negative control in (Figure 3.7 G+ H) also 
indicates the presence of infiltration of macrophages, spindle shaped cells and 
deposition of tar in airways.  
COPD ex-smokers also indicated the presence of airways thickening and squashed 
structure of lung parenchyma. (Figure 3.8 A+ B) shows the expression of epithelial 
marker S100A4 and black arrows pointing towards the capillaries present in the 
tissue section with positive brown cells in the epithelium. GC receptor expressing 
variant TTC5 in (Figure 3.8 C+ D) shows the presence of type ii pneumocyte (black 
arrows) and presence of lymphocytes in epithelial layer. GC receptor expressing 
variant S211 in (Figure 3.8 E+ F) shows precise positive reaction by expressing in 
the upper layer of epithelial cell lines and shows the presence of large number of 
macrophages. Negative control shows the infiltration of macrophages (Figure 3.8 G) 
and lymphocytes indicating inflammation (Figure 3.8 H). 
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FIGURE 3.7 IHC OF COPD CURRENT SMOKER 
Human lung tissue specimen from a COPD current smoker stained for S100A4, TTC5 and 
S211 compared to negative control. Figure 3.7 A+B shows presence of tar deposits and 
capillaries (black arrows). Figure 3.7 C indicates infiltration of lymphocytes and figure 3.7 D 
shows pigmented macrophages denoted by M. in figure 3.7 E+F alveolar detachment and 
spindle shaped brown cells are seen (black arrows). In figure 3.7 G+H black arrows 
indicates the deposition of tar + infiltration of macrophages. X100 magnifications (column A) 
and X400magnifications (column B). 
 
 
 
   
  
87 | P a g e  
 
 
 
 
FIGURE 3.8 IHC OF COPD EX-SMOKER 
Human lung tissue specimen from a COPD ex-smoker stained for S100A4, TTC5 and S211 
compared to negative control. Figure 3.8 A+B shows positive cells for S100A4 and 
capillaries (black arrows). Figure 3.8 C+D shows type ii pneumocytes (black arrows). In 
figure 3.8 E+F black arrow indicates thicker epithelial cell line with positive cells for S211. In 
negative control figure 3.8 G+H shows infiltration of macrophages and lymphocytes. X100 
magnifications (column A) and X400 magnifications (column B). 
 
  
   
  
88 | P a g e  
 
3.3 STATISTICAL ANALYSIS 
 
A comparison study was conducted to assess the study groups between control 
subjects and COPD subjects. A non-parametric one-way ANOVA (Kruskal-Wallis) 
test was performed between the individual study groups (Non-Smoker, Ex-Smoker, 
Current Smoker, COPD Current Smoker and COPD Ex-Smoker). Also, to assess the 
effects of current smoking and previous smoking patients were carried out by 
splitting up Current (COPD and Control) smokers, Ex (COPD and Control) smokers 
and Non-Smokers for data analysis. 
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FIGURE 3.9 COMPARISONS OF BIOMARKERS BETWEEN NON-SMOKER (NS), 
EX-SMOKER (EX), CURRENT SMOKER (CS) WITH COPD EX-SMOKER (CEX) & 
COPD CURRENT SMOKER (CCS). 
A-C: Comparison of positive percentage area stained for S100A4, TTC5 and S211 between 
the separate patient groups. D-F: Comparison of positive percentage area stained for 
S100A4, TTC5 and S211 between the split into smoking status groups (regardless of if the 
subjects has progressed to COPD). Data are presented as mean % area stained (± s.e). 
Following ANOVA unpaired t-tests were performed to determine significance between 
groups. P<0.05 was taken as significant. 
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3.3.1 COMPARISON OF BIOMARKERS Vs ALL PATIENTS SUBJECTS AND 
SMOKING STATUS SUBJECTS 
 
A one-way (Kruskal-Wallis) ANOVA was performed for all patient groups including 
healthy (NS) non-smoker (n=5), (EX) ex-smoker (n=13), (CS) current smoker (n=8) 
with (CEX) COPD ex-smoker (n=11) and (CCS) COPD current smoker (n=8). The 
graph shows extremely significant difference (p<0.0001) in EMT marker S100A4 
expression in lung tissue between then healthy NS, EX, CS and COPD (CCS + CEX) 
(Figure 3.9 A). The significance in expression is clearly observable as rise in 
expression in the ex-smokers compared to never smokers. These raised levels 
remain high in current smokers and ex and current smokers with COPD. 
In (Figure 3.9 B), the ex-smoking groups (EX and CEX) show the highest percentage 
TTC5 expression compared to never smokers (NS) with a very significant difference 
(p=0.0022). Levels of TTC5 expression remain high in current smokers (CS and 
CCS) regardless of COPD development or not. The graph represents very significant 
difference (p=0.0020) in S211 expression among the EX, CS, CCS and CEX 
compared to NS (Figure 3.9 C). Ex-smokers (EX and CEX) show the significant 
difference compared to never smokers and remains high in current smokers (CS) 
and COPD current (CCS) and ex-smokers (CEX). 
In smoking status group, there is also an extremely significant difference (p<0.0001) 
of mean between non-smokers (NS) and ex-smokers (EX) in EMT marker S100A4 
(Figure 3.9 D) and it shows high percentage of marker present in current smokers 
compare to lower percentage in never smokers. S100A4 expression levels are 
similar between ex-smokers and current smokers. One way ANOVA with post –test 
was also performed between non-smoker (NS) and ex-smoker (EX), the results 
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shows extremely significant difference between both the groups (***p<0.05) data not 
shown. This indicates the smoking elevates the expression of S100A4 in smoking 
individuals.  
The TTC5 expression levels (Figure 3.9 E) among the patient groups shows very 
significant difference as (p=0.0068). Ex-smokers show the highest expression levels 
compared to current smokers and non-smokers. Performing the one way ANOVA 
with post-test for TTC5 represents very significant (**p=0.0023) difference between 
non-smokers (NS) and ex-smokers (EX). But comparing both the ex-smokers (EX) 
and current smoker (CS) doesn’t show any difference (P>0.05) data not shown. 
The S211 expression levels shows very significant difference (p=0.0078) among the 
smoking patient groups (Figure 3.9 F). Ex-smokers and current smokers show the 
high percentage expression of marker compared to never smokers. By comparing 
non-smoker (NS) and ex-smoker (EX) with one way ANOVA post-test, it shows very 
significant difference (**p=0.0037) data not shown but no difference was found 
between ex-smoker (EX) and current smoker (CS). 
3.3.2 COPD PATIENTS VS CONTROL SUBJECTS 
 
The following analysis was performed to evaluate if biomarker expression levels 
were different between control subjects (including never smokers, current smokers 
and ex-smokers) compared to those subjects who had gone on to develop COPD 
(including current and ex-smoking patients). 
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FIGURE 3.10 COMPARISON BETWEEN COPD AND CONTROL SUBJECTS 
Comparison of Epithelial Mesenchymal Transition marker S100A4, Glucocorticoid Receptors 
co-factors TTC5 and phosphorylated Glucocorticoid receptor S211 between COPD and 
control subjects. 
 
The Mann-Whitney test was performed to determine the total percentage area 
between Control (Never smokers, Current smokers and Ex-smokers) subjects and 
COPD current and ex -smoker’s subjects. 
C 
A B 
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Figure 3.10 A, the expression of biomarker S100A4 show high level in COPD 
patients group compared to control subjects with no significance difference 
(p=0.3641). 
TTC5 expression levels in Figure 3.10 B show high percentage in COPD patient 
group compared to control subjects but with no significant difference (p=0.3914). 
In Figure 3.10 C, the comparison of S211 expression among the control subjects 
show higher level compared to COPD with no significant difference (p=0.1716). 
Overall, all three biomarkers (S100A4, TTC5 and S211) in control subjects and 
patients there is no notable difference in biomarker expression shown by p>0.05 for 
each of the three comparisons. This again supports the evidence that smoking alone 
raises biomarker expression regardless of lung obstruction and the development of 
COPD. 
 
3.3.3 BIOMARKER EXPRESSION CORRELATION WITH LUNG FUNCTION 
 
A linear regression was performed for the complete data sets to evaluate the 
expression of S100A4, TTC5 and S211 in relation to lung function (percentage 
predicted FEV1, FEV1%) and smoking. Graphs confirm all 3 biomarkers, that 
expression did not alter significantly due to development of obstruction (reflected by 
declining lung function performance %predicted FEV1). 
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FIGURE 3.11 LINEAR REGRESSIONS OF BIOMARKERS AND LUNG FUNCTION  
Linear Regression of lung function FEV1% Predicted and % area stained for Epithelial 
Mesenchymal Transition marker S100A4, Glucocorticoid receptor co-factor TTC5 and 
phosphorylated glucocorticoid receptor S211. 
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3.3.4 PACK YEAR HISTORY 
 
Conversely, analysis of smoking effects shows S100A4 and S211 (significantly) have 
clear trends of positive correlation; indicating rising expression levels with clinically 
assessed smoking pack year history. This trend is not evident for TTC5.  
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FIGURE 3.12 LINEAR REGRESSIONS OF BIOMARKERS AND PYH 
Linear Regression of pack year history and percentage area stained for A) EMT marker 
S100A4, B) GC receptor co-factor TTC5 and C) Phosphorylated GC receptor S211. 
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4. DISCUSSION 
 
The investigation and characterisation of fibrosis and glucocorticoid resistance in 
COPD was carried out with human lungs resections from different patient categories 
ranging from never smoked to COPD smokers with different biomarker antibodies 
and was verified by immunohistochemical staining (IHC) and antibody optimisation. 
Staining and optimization of the epithelial biomarker S100A4  (no pre-treatment 
required), GC receptor co-factor TTC5 (no pre-treatment required) and 
phosphorylated GC receptor site expressing biomarker S211 in EDTA buffer pH 8 
were effectively conducted with 1: 2500, 1:500 and 1:1000 dilutions respectively . 
The quantification and statistical analysis of microscopic images was done via 
GraphPad prism and Instat 3. in 1:2500 in 1:500 in 1:1000 
EPITHELIAL MESENCHYMAL BIOMARKER S100A4: 
The results obtained for S100A4 from IHC findings and statistical analysis represent 
airway remodelling in current, COPD current smokers and COPD ex-smokers. 
Higher expression rises in active smokers and continue to be high in the ex-smokers 
and COPD smoker’s subjects. 
S100A4 is a specific marker of both fibroblasts and the EMT that epithelial cells 
undergo in response to injury (Iwano et al, 2002, Okado et al, 1997 & Zeisberg et al, 
2007). The injury induced inflammation mediates EMT which in turn results in fibrosis 
(Thiery& Sleeman, 2006). From these observations, S100A4 may play a central role 
in fibrotic pathology. 
Our findings show similar aspects to the research work conducted by Sohal and 
group on airway biopsies of COPD current smokers (n=17), COPD ex-smokers 
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(n=15), healthy smokers (n=16) and non-smoking control subjects (n=15). A 
thickened and fragmented epithelium membrane with elongated clefts show positive 
expressions of mesenchymal biomarkers in cells with S100A4, Vimentin and MMP-9. 
This represents EMT may be actively present in active smokers and COPD smokers. 
(Sohal et al, 2010). 
A study on primary epithelial cells from non-smokers (n=5), smokers (n=12) and 
COPD smokers (n=15) suggests that EMT is present in small bronchi of smokers 
and patients with COPD. EMT expressions were raised in human bronchial epithelial 
cells (HBEC) and cigarette smoke extract (CSE) promotes EMT through the 
activation of intracellular ROS, the release of TGF-β, the phosphorylation of ERK1/2 
and Smad3 as well as by the downregulation of cAMP, which may contribute to the 
thickening of the wall of the small airways, caused by fibrosis (Milara et al, 2013). 
Historically, S100A4 has been expressed as fibroblast specific protein-1 (FSP1) 
marker in kidney fibrosis and it has been verified that TGF-ß1and epidermal growth 
factor induces the expression of S100A4 in renal tubular epithelium undergoing EMT 
in vivo (Iwano et al, 2002). Similarly, role of S100A4 has been observed in other 
diseases including liver fibrosis where S100A4 expressing cells increase fibrosis by 
EMT in hepatocytes (Zeisberg et al, 2007). In cardiac hypertrophy (cardiac fibrosis in 
mice) growth and regeneration of injured heart is regulated by EMT involving 
S100A4 induced by TGF-ß and is reversible by BMP-7 (Inamoto et al, 2000, 
Zeisberg et al, 2007 & Storm et al, 2004).  However, Strutz et al did not observe 
staining of endothelial cells, nor of any cells in the heart and liver of mice (1995). The 
explanations that account for such observations may be due to species-specific 
differences in S100A4 mRNA and protein expression or S100A4 may be post-
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transcriptionally regulated (Ambartsumian et al, 1998 & Davies et al, 1995) implying 
that the expressions of S100A4 mRNA and protein may not correlate.  
Mahmood et al, 2015 work focuses on small vs large airways of smokers with 
chronic airflow limitation (CAL), wherein large airways showed characteristics of 
Type –3 EMT and small airways predominates TYPE-2 EMT and is thought to be 
especially profibrotic and might be more related to small airway obstruction and 
obliteration. The relationship seen between the fibrotic marker S100A4 and airflow 
obstruction would certainly fit with this.  
Our research shows a significant raised expression of S100A4 in active smokers 
(Control subjects) and EMT is evident in smoker’s airways but also high levels are 
found in ex-smokers it’s an irreversible process. Cigarette smoke is the highest risk 
factor for causing COPD disease. Cigarette smoke generates large number of free 
radicals (ROS) which in turn activates the oxidative stress originated from 
neutrophils and macrophages (Ya & Rahman, 2011). ROS derives directly from 
mainstream smoke in gaseous form and activate ERK-% (BMK-1) via C-Src Kinase, 
which is thought to be an activator kinase of HIF-1α (Jung et al, 2008). 
Reimann and collegues, (2015) shows up-regulation of S100A4 mRNA in 
microdissected intrapulmonary arteries from explanted end-stage COPD patients 
and mice exposed to 8 months cigarette smoke. High S100A4 expression was 
observed in pulmonary arteries and in non-muscularized vessels with a diameter of ̴ 
50 µm. These findings may point to a role of S100A4 in vascular remodelling. The 
end stage COPD patients have frequent occurrence of hypoxemia (Weitzenblum et 
al, 2005), whereas Barbera et al, showed vascular remodelling in smokers with 
normal lung function or mild COPD patients without hypoxia indicating the other 
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mechanism other than hypoxemia are causative for pulmonary hypertension in 
COPD and in earlier stages (2013). The murine model in Reimann et al, (2015) study 
does not suffer from hypoxemia. This supports the hypothesis that S100A4 may be 
involved in early vascular remodelling even in non-hypoxic, mild-COPD stages. 
TGF-ß is one of the important cell-regulatory networks which drives EMT, particularly 
its isoform TGF-ß1 (Willis & Brook, 2007, Takizawa et al, 2001 & Zhang et al, 2009).  
TGF-ß1 induces EMT in mouse kidneys with a concomitant increase in S100A4 
expression that similarly can be reversed by the BMP7 treatment via activation of 
Smad proteins (Iwano et al, 2002). This places S100A4 as a key regulator of the 
downstream processes in kidney fibrosis and EMT.  
TGF-ß1 can induce EMT in human alveolar and bronchial epithelial cells via Smad 2 
activation (Kasai et al, 2005). TGF-ß transmit signals through its serine-threonine 
kinase receptors which upon activation are internalized into early endosomes where 
it associates with ‘Smad anchor for receptor activation’ which modulates the 
formation of complexes with Smad 2 or Smad 3 (Willis & Brook, 2007). Majority of 
TGF-ß target genes are controlled through Smad-3 dependent transcriptional 
regulation (Ju et al, 2006). Evidence of EMT driver TGF-ß1 in asthma and chronic 
bronchitis in human lung mucosal biopsies shows correlation between thickness and 
basement membrane and increased expressions of TGF-ß1 (Vignola et al, 1997). 
The expression of TGF-ß1 mRNA in small airway epithelium from smokers and 
patients with COPD was significantly higher than in non-smoker controls (Takizawa 
et al, 2001). Soltani et al, (2012), showed an increased expression of vessel 
associated TGF-ß in bronchial reticular basement membrane (RBM) in COPD and in 
normal smokers, but didn’t observe rise in epithelium in large airway biopsies. Apart 
from TGF-β, uPAR signalling pathway may be present in small airway tissue from 
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COPD (Wang et al, 2013) or increased cyclic monophosphate activity in EMT in the 
airways (Milara et al, 2013). There is a great possibility that other signalling 
pathways may play significant role by participating in progression of COPD disease 
at different stages.  
In COPD, fibrosis and inflammation are involved and these both processes are 
greatly depending on tissue remodelling and cell motility. Extracellular S100A4 pass 
signal in paracrine manner via RAGE receptor to promote cell motility (Belot et al, 
2002) These expression and function correlates with and likely promotes EMT in 
several diseases (Thiery & Sleeman, 2006 & Lee et al, 2006). 
RAGE is highly expressed during development, especially in the brain, but its 
expression level decreases in adult tissues. Neurons, smooth muscle cells, 
mesangial cells, mononuclear phagocytes, hepatocytes and cardiac myocytes 
possess low level but in lung tissues high levels were found (Brett et al, 1993). The 
interaction of S100A4 and RAGE was first shown in human articular chondrocytes by 
immunoprecipitation (Yammani et al, 2006). Multi-ligand receptor RAGE interacts 
with serotonin for S100A4 mediated proliferation and migration of human pulmonary 
artery smooth muscle cells (Lawrie et al, 2005 & Spiekerkoetter et al, 2005). 
Pulmonary S100A4 may play an important role via several mechanisms, messenger 
RNA (mRNA) and protein levels increase in fibroblasts during administration of 
bleomycin in pulmonary fibrosis (Lawson et al, 2005) and also in bronchial epithelial 
cells of transplanted lungs (Ward et al, 2005). The interaction of extracellular 
S100A4 and RAGE in colorectal cancer (CRC) cells showed hyperactivation of the 
MAPK/ERK and the hypoxia signalling pathway (Dahlmann et al, 2014).  
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Upregulation of S100A4 under hypoxia is induced via HIF transcription factors 
(Kwapiszewska et al, 2005). Guo et al, 2012 showed that nicotine, a major 
component of cigarette smoke induces HIF-1α expression via mitochondrial reactive 
oxygen species in human small cell lung cancer cells. HIF independent but ROS 
dependent regulation of S100A4 has been postulated but upregulation of S100A4 in 
COPD lungs in absence of hypoxia via ROS and HIF have to be determined by 
further studies. 
Reimann and colleagues (2015) highlighted vascular remodelling in COPD with 
increase in S100A4 expression (FSP1) in vasculature of Human COPD and murine 
lungs, but there is no clear information how S100A4 account for increase in vascular 
remodelling. So recently Sohal S, (2016), proposed the process of endothelial to 
mesenchymal transition (EndMT) may be the possibility in COPD lungs. 
Smoking may put patients at risk of development of EMT and because levels are 
high in ex -smokers, it appears to be a non-reversible process. If the levels had been 
lower than current smokers, this would have indicated a reversibility of the process 
and therefore a benefit to quitting smoking.  The data in this research appears that 
there may be no benefit to quitting smoking once the change in biomarker 
expression is onset. Therefore, this research supports the emphasis on continued 
better education and preventing of smoking habit development in the population. 
GLUCOCORTICOSTEROID RECEPTORS: ROLE OF TTC5 AND S211: 
We investigated the role of biomarkers of glucocorticoid steroid receptor expressing 
cofactor TTC5 and GC receptor phosphorylated site S211. The co-factor and 
phosphorylation status of GR was analyzed by IHC using the cohort of 45 patients 
with different categories- (Non-Smoker=5, Ex-Smoker=13, Current Smoker= 8, 
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COPD Current Smoker=8 and COPD Ex-Smoker= 10) in relation to lung function 
(FEV1% Predicted), smoking. Our findings of IHC show that both TTC5 and S211 
were expressed in all patient groups- peripheral lung tissue, epithelial cell lines and 
macrophages. Statistically a significant difference was observed among the ex-
smokers in TTC5 and S211 compared to other groups. 
TOTAL GLUCOCORTICOID RECEPTORS: 
Steroid receptors are major class of nuclear receptor representing ligand activated 
transcription factors, known to regulate many cellular functions, including 
inflammatory process, energy production and apoptosis (Evans et al, 2005). In 
humans, homeostasis is maintained by a glucocorticoid ‘cortisol’ in adrenal cortex via 
hypothalamic-pituitary-adrenal (HPA) axis and are effective anti-inflammatory drugs 
used to control both acute and chronic inflammatory responses in wide range of 
diseases (Chrousos, 2000). Glucocorticoids are current pharmacologic treatment for 
COPD. However, COPD patients responds poorly to inhaled and oral 
glucocorticoids, even at high doses. The inflammatory response seen in the lungs of 
COPD patients is glucocorticoid insensitive (Barnes & Adcock, 2009). 
Glucocorticoids diffuse across cell membrane and interact with glucocorticoid 
receptors (GR) inside the cytoplasm and mediate hormone-induced actions. GR is a 
molecular protein with domain carrying distinct regions (Gigurer, 1986). The two 
isoforms-hGRα and hGRβ are generated on splicing of hGR. GR is localized in 
alveolar wall, airway epithelium and vascular endothelial cells (Adcock et al, 1996 & 
Pujols et al, 2004). GRβ resides in the nucleus of cells whereas GRα is in the 
cytoplasm and translocate to the nucleus upon ligand binding (Oakley et al, 1999).  
Grα is the predominant isoform of the receptor, it has steroid binding activity and 
   
  
103 | P a g e  
 
mediates either transactivation or trans repression of target genes (Reichardt, 1998), 
whereas GRβ does not bind to glucocorticoids and is unable to trans activate 
glucocorticoid responsive genes (Oakley, 1996 & Hechkt et al, 1997). Furthermore, 
when hGRβ was transiently transfected together with hGRα, a dominant negative 
effect was observed on hGRα (Oakley et al, 1996) and mineralocorticoid receptor 
(Bamberger et al, 1997), leading to the hypothesis that the cellular ratio of hGRα to 
hGRβ may have profound influence on cells sensitivity to glucocorticoids. Each GR 
isoform originating from alternative processing of the GR gene is subject to a variety 
of post translational modifications that further modulate its function and expand 
glucocorticoid signaling.  
Our collaborator in The Salford University Walid and group 2015, investigated effects 
of dexamethasone on total glucocorticoid receptors (TGR), phosphorylated 
expressing GR sites S211, S226 and co-factor TTC5. They show upregulated effects 
of TTC5 with the dexamethasone in A549 lung cell lines and it represents strong 
interaction with S211 and their findings were consistent to Demonacos et al, 2011 of 
TTC5 can interact with TGR at multiple sites in absence or presence of 
dexamethasone. Furthermore, this group conducted IHC with patient demographics 
ranging from non-smoker to COPD subjects and their finding represents TGR, S211 
and TTC5 expressed relatively high in both macrophages and epithelial cell lines of 
control subjects and COPD subjects. But S226 was expressed low in macrophages 
of control and no expression was found in epithelial cell lines of COPD subjects. Our 
findings of IHC shows relatively similar results as TTC5 and S211 are both 
expressed in macrophages and epithelial cell lines. To gain further insight for 
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glucocorticoid receptors expressing components; co-factor TTC5 and 
phosphorylated expressing biomarker S211 were chosen to strengthen the data.  
TTC5 or STRAP regulates the expression of GR target genes involved in 
inflammation. It acts as a cofactor for GC and estrogen receptors (Davies et al, 
2011). TTC5 plays an important role in DNA damage and heat shock factors. It 
induces the interaction of JMY and p300 and increases the HAT activity of p300. 
This leads to enhancement of p53 acetylation, stability and transcriptional activity 
during DNA damage response (Demonacos et al, 2001). TTC5 is associated with 
heat shock factor 1 in a chromatin bound complex which includes p300 and resides 
on promoter region of HSF gene, required to prevent apoptosis (Xu et al, 2008). 
Prevention of apoptosis is linked with TTC5 in acute myeloid leukemia (AML) cells 
(Lynch et al, 2013).  
Corticosteroids bind to the cytoplasmic glucocorticoid receptor (GR); this complex 
translocate into the nucleus where it suppresses pro-inflammatory gene transcription 
(trans- repression) or activates anti-inflammatory gene expression (transactivation) 
(Barnes, 1998). GR phosphorylation is most identified and studied modification 
(Galliher-Beckley et al, 2009 & Beck et al, 2009). The structure of the bound 
glucocorticoid can influence both the pattern and extent of GRα phosphorylation 
(Avenant et al, 2010). A study carried out by Pujols et al, 2004 shows that different 
responses to glucocorticoids in steroid sensitive and steroid insensitive interstitial 
lung diseases were related to changes in the pattern of expression of GRα and GRβ 
isoforms.  
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Phosphorylation within the GR N-terminus occurs during GR activation, with serine 
(S) 211 and 226 phosphorylation associated with GR-ligand nuclear translocation 
and nuclear export respectively (Galliher-Beckley & Cidlowski, 2009). The ability of 
S211 phosphorylation to alter cofactor/corepressor activity may also account for 
changes in gene expression patterns in reducing inflammation. Hence, S211 
phosphorylation site was preferred.  
Plumb et al, (2013), evaluated the GC receptor function in COPD lung macrophages. 
GR was phosphorylated at S203, S211 in small airway epithelium and cells within 
the submucosa in lung tissue of COPD patients, smokers and non-smokers but S226 
doesn’t show any sign phosphorylation. The levels of phosphorylated GR in lung 
macrophages do not differ between COPD patients and controls on a group mean 
basis. However, GR activity may be determined by the relative expression of GR 
isoforms; whereas GRα is important for mediating the anti-inflammatory actions of 
glucocorticoids, GRβ has been shown to inhibit the activity of GRα (Bamberger et al, 
1995).  The levels of GRβ protein have been shown to be increased in BAL 
macrophages of steroid insensitive asthmatics compared to steroid sensitive 
asthmatics and this corresponds with reduced nuclear translocation of GRα (Goleva 
et al, 2006). It has been shown that the levels of GRβ mRNA are increased in the 
peripheral blood neutrophils of COPD patients compared to healthy subjects (Milara 
et al, 2014). 
One of the major effects of GRα phosphorylation is that it changes the transcriptional 
activity of the receptors.  Reports showed that phosphorylation at S211 correlated 
with increased transcriptional activity of GRα, whereas phosphorylation at S226 
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decreased the signaling capacity of the receptor (Wang et al, 2002 & Chen et al, 
2008). A deficiency in S211 phosphorylation might contribute to the resistance to 
glucocorticoid induced apoptosis that develops in malignant lymphoid cells (Miller et 
al, 2005).  
The relative lack of response to corticosteroids has been linked to oxidative stress. 
Cigarette smoking is the major culprit in causing COPD. Cigarette smoke contains 
more than 2000 xenobiotic compounds and 1015 free radicals (ROS) per puff causing 
damage to airways and lung epithelial cells (Ya & Rahman, 2011).  This suggests 
that oxidative stress may be an important factor in inducing corticosteroid resistance 
in COPD. Corticosteroids showed less effectiveness in reducing inflammatory cells in 
BAL & sputum from smoking asthmatic patients compared to non-smokers 
(Chalmers et al, 2002 & Chaudhari et al, 2003).  The resistance to corticosteroid 
action is maintained even in subjects who are no longer smoking. This implies that 
either the oxidant stress is persistent or that the initial chronic insult permanently 
alters the expression of a component involved in corticosteroid action.  Okamoto et 
al, (1999) suggested that oxidative stress may influence corticosteroid function by 
inhibiting GR nuclear translocation or cigarette smoke can suppress GR function 
without affecting nuclear translocation (Adcock et al, 2005).  
In our findings, the expression of TTC5 and S211 didn’t alter during the evaluation of 
all patient groups in relation with forced expiratory volume in 1 second FEV1% 
predicted. On contrary, S211 shows raised expression level and positive correlation 
with smoking pack year history, indicating smoking alone is responsible for increased 
level despite of lung obstruction in COPD disease.  
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Other proposed mechanisms for reduced corticosteroid function involve nuclear 
events. Oxidant- mediated enhancement of inflammatory responses and 
development of relative glucocorticoid insensitivity may be facilitated by alteration of 
acetylation-deacetylation balance of core histones (Rahman et al, 2004). Gene 
transcription is controlled by histone acetyltransferases (HAT) and histone 
deacetylases (HDACs) are important for corticosteroid mediated suppression of NF-
kB activity. Oxidative stress leads to reduction of HDAC2 expressions in in vivo and 
in vitro (Ito et al, 2001 & Marwick et al, 2004). The expression and activity of HDAC2 
is decreased in BAL macrophages and biopsy specimens from smokers and 
correlates with COPD (Barnes et al, 2004). These decrease in HDAC2 activity 
correlates with increased inflammatory gene expression and reduced 
responsiveness to corticosteroids (Ito et al, 2001).  
The activation of signaling kinases is a fundamental part of physiologically controlled 
inflammation. COPD patients display altered kinase signaling with an elevation in the 
activity of p38 MAPK and JNK compared to healthy smokers (Renda et al 2008 & 
Rumara et al, 2008). The inflammatory gene expression in patients with reduced 
corticosteroid sensitivity may be associated with increased phosphorylation of GR at 
serine 226by p38 MAPK, which results in reduced nuclear translocation and failure 
of GR to inhibit gene transcription (Mercado et al, 2012).  
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5. CONCLUSION AND FUTURE PERSPECTIVES 
Chronic obstructive pulmonary disease is characterized by airflow obstruction that is 
progressive and not fully reversible and associated with chronic airway inflammation. 
Smoking is considered to be the crucial player in COPD. It contributes to the 
underlying structural changes and airway remodeling. To our knowledge the process 
applicable for remodeling of airways involves the differentiation of epithelial into 
mesenchymal cells (EMT). During injury or wound healing, myofibroblast cells are 
activated via inflammation. This can cause fibrosis and destruction of alveoli. The 
tissue remodeling lead to airflow obstruction and thickening of small airways with 
infiltration of inflammatory cells. However, the source of fibroblasts is unknown. It is 
assumed that they arise from trans-differentiation of residential pulmonary 
fibroblasts. They can be an effector cell in fibrotic respiratory disease like COPD.  
 
I have contributed to the FIR group at The Salford University and shown the EMT 
biomarkers are linked to COPD. They observed S100A4 was highly expressed in 
COPD tissues of active smokers and COPD subjects and linked to smoking in 
disease progression. Our study is of course limited by the fact that it was carried out 
in living human subjects underwent surgery. Further study with larger group may get 
require to broaden our results of EMT in COPD. However, my research presented in 
this thesis strengthens the previous data from the FIR group and will contribute to a 
publication to be submitted to CHEST journal soon.  
Our findings have shown the raised expression of S100A4 in active smokers. 
Smoking can put patient at a risk of development of EMT, which indicates, EMT 
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process may contribute a potential role in fibrosis of COPD by being partly 
reversible. Researches have shown a quite strong evidence that airway epithelium 
can undergo EMT of human airways in smokers and would explain the underlying 
pathological processes involved in COPD and its accompanying risks. The functional 
effect of S100A4 in cell motility plays a general role in disease progression by tissue 
remodeling of both tumor and non-tumor related tissues of normal cells in kidney, 
liver and heart. However, it is not clear whether the processes that S100A4 induces 
are similar in lung fibrosis. Several pieces of data have prompted speculations on 
whether S100A4 could be used as a prognostic marker for fibrotic diseases like it is 
used for cancer. As some evidence show S100A4 is involved in both tissue fibrosis 
and metastasis. Though S100A4 plays a major role in EMT, additional research is 
required to understand the precise molecular interactions that lead specifically to 
EMT in the airways in response to cigarette smoke. To understand this molecular 
mechanism, EMT can be observed in lung biopsies via profound histochemical 
analysis, laser capture dissection microscopy or by bronchoscopy.  
Glucocorticoids act through the GR to regulate numerous physiologic processes, and 
synthetic derivatives of these hormones are widely prescribed for treating 
inflammatory diseases. The discovery of multiple isoforms of GR from single gene 
has advanced our understanding in molecular mechanism in glucocorticoid signaling. 
Though, Glucocorticoid resistance remains a major barrier to effective treatment of 
variety of inflammatory diseases including COPD.  
A collaborative group of The Salford University has been working on different 
glucocorticoid receptors and GC receptor variants expressing in lungs. The research 
   
  
110 | P a g e  
 
conducted by this group on COPD patients and control subjects observed the effect 
of dexamethasone (dex) on TGR, phosphorylated GR at S211 and S226 and on 
stress co-factor TTC5 suggesting that protein levels of both phosphorylated forms of 
GC receptors is upregulated in the presence of dex hormone and observed 
interaction between TTC5 and S211 suggesting transcriptional activity may be 
present. Hypothesis being made that differential expression of GR may exist in 
COPD and control subjects. We also conducted a study on glucocorticoid receptor 
expressing two different variants- Cofactor TTC5 and phosphorylated GC receptor 
S211 in COPD patients Vs control subjects. Our results showed TTC5 and S211 
expression were raised in Ex-Smokers and current smoker but low-level expressions 
were observed in non-smokers. This irreversible change implicates the mechanism 
of steroid resistance in COPD patients. Not all patients with COPD who smoke are 
insensitive to GC for some reason, so some drug will show effectiveness in some 
groups. Therefore rapid test to differentiate the mechanism of defective cells from 
this patient can be useful as a measure for selective therapy.  
Recent investigation on GR provides a novel insight to understand mechanisms of 
GC resistance and increasing knowledge of molecular mechanism by which patient 
loses responsiveness to GCs opens up the possibility of defined patient specific 
therapy. Anti-inflammatory therapies, restoration of GC function by theophylline are 
important therapeutic targets for respiratory diseases like COPD. The isoforms of GC 
receptors may be involved differentially in signaling mechanisms. There can be 
tremendous potential for development of synthetic ligands that activate anti-
inflammatory mechanisms but do not affect other pathways.  
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